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Supplementary Note 77 
 78 
Selecting individuals from UK Biobank  79 
Spirometry Quality Control 80 
UK Biobank contains data for 502,682 individuals. Of these, 445,754 had at least two measures of FEV1 (VariableID: 81 
3063) and FVC (VariableID: 3062), complete information for spirometry method used (VariableID: 23), age 82 
(VariableID: 21022), sex (VariableID: 31) standing height (VariableID: 50), and for whom ever smoking status could be 83 
derived (derivation of ever smoking status described below). For quality control of spirometry, the pre-derived FEV1, 84 
FVC and PEF measurements (VariableIDs: 3063, 3062 and 3064), the blow curve time series measurements 85 
(VariableID: 3066) and the Vitalograph spirometer blow quality metrics (VariableID: 20031) were used.  86 
Acceptability of blows 87 
To identify “acceptable” blows for inclusion in the analyses of FEV1, FVC, FEV1/FVC and PEF, the following quality 88 
control steps were undertaken; 89 
1. Blows were initially deemed to be acceptable if they contained the following values in the Vitalograph 90 
spirometer blow quality metrics; “blank”, “ACCEPT”, BELOW6SEC ACCEPT” and “BELOW6SEC”. A total of 91 
777,676 blows from 387,430 participants were deemed acceptable. 92 
2. Next, start of blow quality was examined. Blows were excluded if the back-extrapolated volume (as defined 93 
using the blow curve time series measurements 1) was less than 5% of FVC or less than 150ml. Following this 94 
exclusion, a total of 776,927 blows from 387,277 participants remained. 95 
3. Finally, a comparison of the pre-derived FEV1 and FVC measurements (VariableID: 3063 and VariableID: 96 
3062) and FEV1 and FVC newly derived from the blow curve time series measurements (VariableID: 3066) 97 
was undertaken. Blows where the pre-derived and newly-derived values differed by 5% were excluded.  98 
Following this exclusion, a total of 776,318 “acceptable” blows from 387,052 participants remained for 99 
further analysis of FEV1, FVC, FEV1/FVC and PEF. Whilst PEF was also pre-derived, we identified a subset of 100 
individuals had unusually low recorded values, which were inconsistent with the PEF values derived from the 101 
time series curves; the predefined PEF values were deemed to be erroneous, therefore no exclusions were 102 
undertaken based on comparisons of pre-derived and newly-derived PEF, and the newly-derived PEF values 103 
were used for association analyses.  104 
Identification of best measures 105 
The “best measure” per individual was defined as the highest measure from the “acceptable” blows for FEV1, FVC. 106 
FEV1/FVC was derived from the selected FEV1 and FVC. For PEF, which is a measure of flow, the best measure was 107 
defined as the blow with the highest acceptable measure of the sum of FEV1 and FVC. This definition meant that a 108 
participant’s “best measures” did not necessarily have to be derived from the same blow. 109 
Reproducibility of measures 110 
To meet the criterion for reproducibility in our analysis, the “best measures” of FEV1 and FVC had to be within 250ml 111 
of those measures from any other blow. The other blow did not need to be acceptable. Where an individual’s best 112 
measures for FEV1 and FVC were not both found to be reproducible, that individual was excluded. 348,936 113 
individuals had acceptable and reproducible measures of both FEV1 and FVC and were eligible for inclusion in 114 
analyses of FEV1, FVC, FEV1/FVC and PEF. 115 
Differences in approach from previous analyses 116 
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The previous approach used for quality control of spirometry data was described in2.  This previous approach utilised 117 
the Vitalograph spirometer blow quality metrics to define acceptability only. In the present analysis, following 118 
recommendations based on work conducted for the UK Biobank Outcomes Adjudication Working Group [Strachan, 119 
personal communication], we have additionally included quality control steps based on the volume-time curves 120 
recorded (at 10ms intervals) for each spirogram. Metrics derived from these curve datasets allowed a more 121 
comprehensive and systematic assessment of: start of blow quality; end of blow quality; length of blow; and 122 
derivation of flow rates. They also permitted a comparison between FEV1, FVC and PEF derived from the curve 123 
datasets and those pre-derived by the spirometer.  124 
The quality control of spirometry data used in our previous publication2 applied the ATS/ERS criteria for assessing 125 
reproducibility. These criteria, which are widely used in clinical practice, recommend that the best measures of FEV1 126 
and FVC are within 150ml of any other blow. However, within UK Biobank a subset of 20,347 participants were re-127 
examined after an interval of 2-7 years, of whom 14,238 (70%) performed two or more spirograms with good start-128 
of-blow and end-of blow quality on both occasions. Analysis of the within-subject between-occasion correlation 129 
(reliability coefficient) of FEV1 and FVC in relation to the reproducibility of these measures at the entry examination 130 
suggested that the ATS/ERS reproducibility threshold was unduly conservative. For epidemiological studies, where 131 
spirometric comparisons are being made between groups rather than for monitoring of individual patients, a more 132 
relaxed reproducibility threshold of 250ml could be applied, increasing the available sample size without 133 
jeopardising the reliability of FEV1 or FVC. 134 
For illustration, among the participants with good start-of-blow and end-of-blow quality, using a reproducibility 135 
threshold of 250mL, FVC reliability was 0.9199, 0.9033, 0.8886, 0.9086 and 0.9071, respectively, for subjects with 136 
intervals of 2, 3, 4, 5 and 6-7 years between the two examinations. The corresponding figures for FEV1 reliability 137 
were 0.9152, 0.9014, 0.8753, 0.8981 and 0.8992. 138 
Definition of smoking status for covariate adjustment of association analyses 139 
Smoking initiation (123,890 ever smoked vs 151,706 never smoked) was inferred using answers from questionnaire. 140 
Never smokers are those individuals who do not smoke at present and never smoked in the past [code 1239=0 & 141 
1249=4] or do not smoke at present, smoked occasionally or just tried once or twice in the past, but had less than 142 
100 smokes in their lifetime [1239=0 &1249=2/3 & 2644=0]. Ever smokers include current smokers (who smoke at 143 
present, on most or all days or occasionally [1239=1/2]), previous smokers (who do not smoke at present and 144 
smoked on most or all days in the past [1239=0 &1249=1] or do not smoke at present, smoked occasionally or just 145 
tried once or twice in the past, and had more than 100 smokes in their lifetime [1239=0 &1249=2/3 & 2644=1]) and 146 
individuals who smoked on most/all days or occasionally in the past, and smoked more than 100 times in their life, 147 
but prefer not to answer about current smoking [1239=-3 & 1249=1 or 1239=-3 & 1249=2 & 2644=1]. 148 
Genotyping quality control 149 
The genotyping procedure, genotype quality control and imputation of the UK Biobank individuals is described in 150 
detail elsewhere.3 968 individuals with outlying heterozygosity or missingness were already excluded from the 151 
provided imputed genotypes. We further excluded 378 individuals for whom the submitted gender did not match 152 
the genetically inferred gender, 977 samples related to >200 other samples, 188 samples with >10 3rd degree 153 
relatives and 471 samples with putative sex chromosome aneuploidy, giving 2,008 excluded samples in total leaving 154 
486,369 samples from which to select our discovery set. 155 
Identification of individuals of European ancestry for inclusion in the genome-wide association analysis of lung 156 
function 157 
K-means clustering was used to identify the set of European- ancestry individuals to include in the genome-wide 158 
association analysis of lung function. The steps taken to define the sets of non-European ancestry individuals to 159 
include in the analysis of heterogeneity of signals is described below. 160 
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Principal components (PCs) were provided with the UK Biobank genetic data. K-means clustering using the first two 161 
PCs was undertaken for between 3 and 8 clusters after excluding 2,008 samples failing genotyping quality control. 162 
The 6 cluster k-means model was selected as most appropriately clustering the 486,369 samples remaining after 163 
genotype quality control (QC) into broad ethnic groups giving 453,958 samples of “European ancestry” 164 
(Supplementary Figure ). This resulted in an additional 45,865 individuals being eligible for inclusion in addition to 165 
the 408,093 passing genotype QC and defined as “white British” by UK Biobank3. 166 
Selecting individuals passing spirometry and genotyping quality control for genome-wide association testing 167 
There was an overlap of 341,102 individuals (321,057 European) between 348,936 passing spirometry quality control 168 
for FEV1, FVC, FEV1/FVC and PEF and 486,369 passing genotyping quality control. 169 
Removal of outlying lung function measures in European samples for discovery GWAS 170 
Adjustment for sex, age, age2, height, and smoking status (ever/never) of each lung function measure was 171 
undertaken in each ancestry category. 10 European individuals were excluded that were obvious outliers in plots of 172 
the adjusted phenotype distributions and the adjustment was repeated. This left 321,047 European individuals for 173 
the discovery GWAS of FEV1, FVC, FEV1/FVC and PEF. 174 
Power Calculations and between-trait correlations 175 
Power calculations were performed with the GeneticsDesign R package 176 
(https://bioconductor.org/packages/GeneticsDesign/) (Supplementary Figure 7) to: 177 
A) calculate the power to detect a signal passing Tier 1 or Tier 2 criteria i.e. P<10-3 in the SpiroMeta cohort of 79,055 178 
samples. At this threshold, there would be 75% power to detect an effect size of 0.0325 standard deviations for a 179 
variant with MAF 10% and 95% power to detect an effect size of 0.122 standard deviations for a variant with MAF 180 
1% in SpiroMeta. 181 
B) calculate the power to confirm a previously reported lung function quantitative trait association in UK Biobank at 182 
P<10-5 (n=321,047). 183 
Effect sizes for previously reported signals range from ~0.025 for MAF > 5% to 0.18 for MAF 2%. 184 
The table below shows the phenotypic correlation between the four different traits in UK Biobank in the upper 185 
triangle (bold), with the genetic correlation in the lower triangle. We did not additionally correct for multiple testing 186 
of 4 phenotypes due to their correlation. 187 
 Phenotypic correlation 
G
en
et
ic
 c
o
rr
el
at
io
n
 
 
FEV1 FEV1/FVC FVC PEF 
FEV1 
 
0.288 0.950 0.846 
FEV1/FVC 0.408 
 
-0.013 0.316 
FVC 0.879 -0.076 
 
0.780 
PEF 0.708 0.621 0.444 
 
Genetic correlations with height were calculated using LD-score regression (undertaken by the LD-Hub team). The 188 
datasets were the Height 2010 GIANT paper4 and the automated GWAS of UK Biobank variables undertaken by 189 
Neale et al.5,6 190 
Phenotypic correlations were undertaken in the Extended Cohort for E-Health, Environment and DNA (EXCEED 191 
cohort, see ‘Cohort contributors’). Correlations are Pearson’s correlations. 192 
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Trait Genetic correlation between height  
(PMID 20881960) and UKB variable GWAS 
Phenotypic correlation with height  
(EXCEED cohort) 
FEV1 (UKB variable 20150) 0.501 [95% CI 0.464, 0.538], P=3.67x10-146 0.64 [95% CI 0.617, 0.654], P<2.2x10-16 
FVC (UKB variable 20151) 0.586 [95% CI 0.549, 0.623], P=1.75x10-203 0.70 [95% CI 0.682, 0.714], P<2.2x10-16 
Overlap of samples and genetic correlation between UK Biobank and SpiroMeta. 193 
Association test statistics were regressed against the LD score of each variant using LDSC5. The proportion of total 194 
inflation due to confounding is (Intercept-1)/(Mean χ2 -1), where χ2 is the mean statistic from the association testing 195 
and the intercept is the intercept of the LD score regression (estimate of inflation due to confounding but not 196 
polygenicity). The proportion of inflation due to confounding in the meta-analysis was low (<4%) (Supplementary 197 
Table 27), hence we did not conclude overlap of samples between UK Biobank and SpiroMeta. 198 
Genome-wide genetic correlation between UK Biobank and SpiroMeta was calculated using LDSC5 and was 0.993 for 199 
FEV1, 0.979 for FVC, 0.946 for FEV1/FVC and 0.964 for PEF. 200 
There were 70 distinct signals of association (‘distinct’ as determined by distance >1Mb and linkage disequilibrium 201 
r2<0.1) that met a threshold of P<5x10-9 in UK Biobank but which did not meet Tier 1, Tier 2 or Tier 3 selection 202 
criteria. Of these of these 70, 12 had P<0.05 in SpiroMeta with a consistent direction of effect. The remaining 58 had 203 
P>0.05 in SpiroMeta and of these, 38 had a consistent direction of effect between UK Biobank and SpiroMeta. 204 
Conditional analysis with GCTA 205 
All SNPs ±1Mb were extracted around each sentinel variant. GCTA7 was then used to perform stepwise conditional 206 
analysis in order to select independently associated SNPs within each 2Mb region using the single SNP association 207 
statistics combined with LD information from reference genotypes representative of the samples in the association 208 
testing. For UK Biobank the same genotype data as used for the initial discovery association testing was used as an 209 
LD reference; for SpiroMeta, genotypes from 48,943 unrelated participants2 formed the LD reference set 210 
Smoking behaviour association analyses in UKB. 211 
Association analyses with smoking behaviour phenotypes were performed in the 335,641 UKB individuals out of the 212 
full 488,377 included in the final release of genetic data that were not in the 152,736 in the interim release 213 
(http://www.ukbiobank.ac.uk/scientists-3/genetic-data/), as part of an independent replication for the GSCAN study 214 
that included samples from the UK Biobank interim release. 215 
Genotyping quality control was performed using the same criteria as for the lung function analysis (individuals 216 
excluded on the basis of sex mismatches, heterozygosity and missingness). Only individuals of European ancestry 217 
were included in the association analyses. These were identified by first calculating the minimum and maximum 218 
value of the first 4 PCs of the samples defined as white British in UK Biobank [ref to QC paper] and then we included 219 
any individual in this PC range regardless of their self-reported ancestry. Individuals who were related to UK Biobank 220 
individuals included in previous releases with a kinship coefficient > 0.075 were excluded from the analyses. Only 221 
variants imputed on the HRC panel and with MAC >= 3 were included in the analyses. 222 
Smoking initiation (123,890 ever smoked vs 151,706 never smoked) was inferred using answers from questionnaire 223 
as for the smoking covariate adjustment above. 224 
The average number of cigarettes smoked per day (CPD) for all individuals who smoke, or smoked, on most or all 225 
days was binned as follows: 1 = 1-5, 2 = 6-15, 3 = 16-25, 4 = 26-35, 5 = 36+. Cigarettes per day was available for 226 
80,015 samples. 227 
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All phenotypes used age, age squared, sex, and genetic principal components 1-15 as covariates. Residuals were 228 
calculated for each phenotype by linear regression, with the phenotype as the dependent variable and the 229 
corresponding covariates as the independent variables. These residuals were then inverse normalized, and the 230 
corresponding Z-scores were used as the input phenotype values for the association analysis.  231 
BOLT-LMM version 2.3 was used to conduct association analysis on each chromosome. The variants included in the 232 
mixed model were extracted from the genotyped variants by applying the following filters: missingness < 5%, minor 233 
allele frequency > 1%, HWE p > 10-6, pruning for LD r2 < 0.2. The hg19 reference map was used to interpolate genetic 234 
map coordinates. BOLT-LMM standard errors (and resulting P-values) were inflated by the LD-score intercept, which 235 
was calculated using LD-scores provided with LDSC,5 calculated from 1000 Genomes Project samples. 236 
Smoking interaction testing 237 
Association testing for lung function was calculated separately in ever and never smoker subgroups and meta-238 
analysed across UK Biobank and SpiroMeta for up to 176,701 ever smokers and 197,999 never smokers. The Welch 239 
test was used to compare genetic effect between ever and never smokers: 240 
𝑡 =  
𝛽1 − 𝛽2
√𝑠𝑒12 + 𝑠𝑒22
 241 
with degrees of freedom: 242 
        243 
𝑑. 𝑓. =  
(𝑠𝑒1
2 + 𝑠𝑒2
2)2
𝑠𝑒12
𝑛1 − 1
+
𝑠𝑒22
𝑛2 − 1
 244 
 245 
A deviation from equality (P<1.8x10-4, i.e. 0.05/279 tests) was considered significant evidence of interaction. For 246 
these analyses, phenotypes were inverse normalised after regressing on sex, age, age2, and height. Genotyping array 247 
was included as a covariate. 248 
Using the European only sample as input for relatedness exclusion here resulted in a marginally bigger sample size 249 
than that produced when including all ancestries (N = 303,619 cf. N = 303,570).   250 
 251 
Area Under the Curve and Population Attributable Risk Calculations 252 
We calculated the area under the curve in the COPDGene Non-Hispanic White population using the pROC package in 253 
R. Two models were compared: a baseline model with COPD as outcome and age, age2, sex, height, smoking (pack-254 
years) and principal components, and then another model with the addition of the weighted genetic risk score. 255 
We calculated the population attributable risk fraction (PARF) as follows: 256 
𝑃𝐴𝑅𝐹 =
𝑃(𝐸)(𝑂𝑅 − 1)
1 + 𝑃(𝐸)(𝑂𝑅 − 1)
 257 
where P(E) is set to 0.9, i.e. the probability of possessing more risk alleles than those in the lowest decile of the risk 258 
score (the ‘probability of the exposure’). OR above refers to the odds of having COPD in individuals across deciles 2 259 
to 10 of the risk score compared to the odds of having COPD for individuals in the lowest decile (decile 1) of the risk 260 
score.  261 
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Before calculating the PARF, we used the European meta-analysis OR of 1.546 (95CI: 1.476-1.620) per SD of the 262 
genetic risk score (GRS) to estimate the OR for COPD, comparing individuals in deciles 2-10 vs those in decile 1.  We 263 
assume that the GRS is normally distributed so that log(1.546) is the additive effect on a standard normal variable. 264 
The expected GRS, given that an individual is in decile j of the GRS, is 265 
1
0.1
∫ 𝑥𝜙(𝑥)𝑑𝑥
Φ−1(
𝑗
10)
Φ−1(
𝑗−1
10 )
 266 
The limits of the integral are the lower and upper values of the GRS for individuals in decile j, assuming the GRS is 267 
standard normal.  The division by 0.1 ensures the expectation is conditional on the individual being in the decile, 268 
which is 1/10 by definition. 269 
Then the expected log OR for decile j is  270 
log (1.546)
0.1
∫ 𝑥𝜙(𝑥)𝑑𝑥
Φ−1(
𝑗
10)
Φ−1(
𝑗−1
10 )
 271 
and comparing with decile 1 gives 272 
log (1.546)
0.1
[∫ 𝑥𝜙(𝑥)𝑑𝑥
Φ−1(
𝑗
10)
Φ−1(
𝑗−1
10 )
− ∫ 𝑥𝜙(𝑥)𝑑𝑥
Φ−1(
1
10)
−∞
] 273 
We can now proceed to estimate the log OR for deciles 2-10 vs decile 1 as 274 
log (1.546) [
1
0.9
∫ 𝑥𝜙(𝑥)𝑑𝑥
∞
Φ−1(
1
10)
−
1
0.1
∫ 𝑥𝜙(𝑥)𝑑𝑥
Φ−1(
1
10)
−∞
] = log (2.339) 275 
The estimated bounds of the 95% confidence interval around this new estimate are then calculated using the same 276 
method, and entered into the PARF equation, above. 277 
SpiroMeta consortium study details 278 
This section provides study descriptions for the cohorts contributing to the SpiroMeta consortium. All participants 279 
provided written informed consent and studies were approved by local Research Ethics Committees and/or 280 
Institutional Review boards. 281 
Details of the British 1958 Birth Cohort biomedical follow-up have been previously reported8. Spirometry at age 44–282 
45 years was done in the standing position without nose clips, using a Vitalograph handheld spirometer as previously 283 
described9. In the analysis, all readings with a best-test variation greater than 10% were excluded. 284 
The Busselton Health Study (BHS) is a longitudinal survey of the town of Busselton in the south-western region of 285 
Western Australia that began in 1966. In 1994/1995 a cross-sectional community follow-up study was undertaken 286 
where blood was taken for DNA extraction. A sample of 1,168 European-ancestry individuals were genotyped using 287 
the Illumina 610-Quad BeadChip (BHS1), and subsequent genotyping was carried out on an independent group of 288 
3,428 European-ancestry individuals using Illumina 660W-Quad (BHS2). Spirometric measures of forced expired 289 
volume in one second (FEV1) and forced vital capacity (FVC) were assessed. 290 
The CROATIA study was initiated to investigate the use of isolated rather than urban populations for the 291 
identification of genes associated with medically-relevant quantitative traits. Three cohorts have been recruited as 292 
part of the CROATIA study: CROATIA-Vis10, CROATIA-Korcula11 and CROATIA-Split12. CROATIA-Vis was the first to be 293 
 11 
 
collected when 1,008 Croatians aged 18-93 recruited from the villages of Komiza and Vis on the Dalmatian island of 294 
Vis. Recruitment occurred from 2003 to 2004 with participants donating blood for DNA extraction and biochemical 295 
measurements as well as undergoing some anthropometric measurements and physiological tests to measure traits 296 
such as height, weight and blood pressure, and finally completing several questionnaires relating to general health, 297 
medical history, diet and lifestyle. CROATIA-Korcula was recruited from 2007 to 2008 from the town of Korcula and 298 
the villages of Lumbarda, Zrnovo and Racisce on the island of Korcula, Croatia with 969 adults aged 18-98 agreeing to 299 
participate. This study followed the same recruitment procedures as CROATIA-Vis and the same samples and tests 300 
were collected with a few additions to reflect the research interests and expertise in Edinburgh. Volunteers were 301 
recruited to be part of the CROATIA-Split cohort in 2009-2010 from the Dalmatian mainland city of Split. This is the 302 
main ferry port to the islands and is the second largest city in Croatia and the largest along the Dalmatian coast. 303 
1,012 adults aged 18-85 were recruited using the same methodology and with the same samples collected as in 304 
CROATIA-Korcula. Ethical approval was obtained from appropriate regulatory bodies in both Scotland and Croatia 305 
and participants gave informed consent prior to joining the study. 306 
European Prospective Investigation of Cancer (EPIC)-Norfolk is an ongoing UK-based prospective cohort and part of 307 
the Europe-wide multi-centre EPIC study.  Details of the study design were described previously.13 Briefly, 25,639 308 
men and women aged 40-79 in eastern England were recruited through general practice registers and underwent 309 
baseline assessment between 1993 and 1997.  Participants were further invited to the follow-up assessment (1998 310 
to 2000), and were followed up by 2009 for incident outcomes and by 2013 for mortality. 311 
The Generation Scotland: Scottish Family Health Study is a collaboration between the Scottish Universities and the 312 
NHS, funded by the Chief Scientist Office of the Scottish Government. GS:SFHS is a family-based genetic 313 
epidemiology cohort with DNA, other biological samples (serum, urine and cryopreserved whole blood) and socio-314 
demographic and clinical data from ~24,000 volunteers, aged 18-98 years, in ~7,000 family groups. Participants were 315 
recruited across Scotland, with some family members from further afield, from 2006-2011. Most (87%) participants 316 
were born in Scotland and 96% in the UK or Ireland. The cohort profile has been published14. GS:SFHS operates 317 
under appropriate ethical approvals, and all participants gave written informed consent. Generation Scotland is a 318 
collaboration between the University Medical Schools and National Health Service in Aberdeen, Dundee, Edinburgh 319 
and Glasgow (UK). 320 
The DNA archive established from the Health 2000 Survey Cohort was used. Details of this study population and 321 
phenotyping procedures have been previously reported15. Genome-wide genotyping was available for 2124 322 
individuals selected from the Health 2000 cohort as metabolic syndrome cases and their matched controls16. 323 
Spirometry was done in the standing position without nose clips, using a Vitalograph 2150 spirometer. In the 324 
analysis, the maximum permissible difference between the two highest FEV1 and FVC values was 10%. 325 
The KORA studies (Cooperative Health Research in the Region of Augsburg) are a series of independent population 326 
based studies from the general population living in the region of Augsburg, Southern Germany17,18. KORA F4 327 
including 3,080 individuals was conducted from 2006-2008 as a follow-up study to KORA S4 (1999-2001). Lung 328 
function tests were performed in a random subsample of subjects born between 1946 and 1965 (age range 41–63 329 
years). Spirometry was performed in line with the ATS/ERS recommendations1 using a pneumotachograph-type 330 
spirometer (Masterscreen PC, CardinalHealth, Würzburg, Germany) before and after inhalation of 200μg salbutamol. 331 
The present study is based on maximum values of FEV1 and FVC measured before bronchodilation. The spirometer 332 
was calibrated daily using a calibration pump (CardinalHealth, Würzburg, Germany), and additionally, an internal 333 
control was used to ensure constant instrumental conditions. For KORA F4 participants without spirometry 334 
measurements in 2006-2008, we used measurements from the KORA-Age time point conducted in 2008/09. KORA 335 
Age contains subjects from all KORA studies born until 1943 (aged 65-90 years)19. Spirometry was measured in 935 336 
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randomly selected participants. Conditions including the examiner were the same as in 2008/09 except that 337 
inhalation of salbutamol was not performed due to the high number of contraindications anticipated in this aged 338 
population.   339 
The KORA studies (Cooperative Health Research in the Region of Augsburg) are a series of independent population 340 
based studies from the general population living in the region of Augsburg, Southern Germany17,18. The KORA S3 341 
study including 4,856 individuals was conducted in 1994/95. Spirometry was measured during a follow up in 1997/98 342 
for all participants younger than 60 years who did not smoke or use inhalers one hour before the test. All spirometric 343 
tests were performed strictly adhering to the ECRHS protocol20,21 using Biomedin Spirometers (Biomedin srl, Padova, 344 
Italy). Tests were accounted valid if at least two technically satisfactory manoeuvres could be obtained throughout a 345 
maximum of nine trials. FEV1 and FVC were defined as the maximum value within all valid manoeuvers. For KORA S3 346 
participants without spirometry measurements in 1997/98 we used measurements from the KORA-Age time point 347 
conducted in 2008/09. KORA Age contains subjects from all KORA studies born until 1943 (aged 65–90 years) 19. 348 
Spirometry was measured in 935 randomly selected participants. Conditions including the examiner were the same 349 
as in KORA F4 (see below) except that inhalation of salbutamol was not performed due to the high number of 350 
contraindications anticipated in this aged population.   351 
The Lothian Birth Cohort 1936 consists of 1,091 relatively healthy individuals assessed on cognitive and medical 352 
traits at about 70 years of age. They were all born in 1936 and most took part in the Scottish Mental Survey of 1947. 353 
At baseline the sample of 548 men and 543 women had a mean age 69.6 years (s.d. = 0.8). They were all Caucasian, 354 
community-dwelling, and almost all lived in the Lothian region (Edinburgh city and surrounding area) of Scotland. A 355 
full description of participant recruitment and testing can be found elsewhere22. Genotyping was performed at the 356 
Wellcome Trust Clinical Research Facility, Edinburgh. Quality control measures were applied and 1,005 participants 357 
remained. Lung function assessing peak expiratory flow rate, forced expiratory volume in 1 second, and forced vital 358 
capacity (each the best of three), using a Micro Medical Spirometer was assessed, sitting down without nose clips, at 359 
age 70 years. The accuracy of the spirometer is ±3% (to ATS recommendations Standardisation of Spirometry 1994 360 
update for flows and volumes). 361 
The Northern Finland Birth Cohort 1966 (NFBC1966) is a prospective follow-up study of children from the two 362 
northernmost provinces of Finland born in 1966.23All individuals still living in northern Finland or the Helsinki area (n 363 
= 8,463) were contacted and invited for clinical examination. A total of 6007 participants attended the clinical 364 
examination at the participants’ age of 31 years. DNA was extracted from blood samples given at the clinical 365 
examination (5,753 samples available).24 The subset with DNA is representative of the original cohort in terms of 366 
major environmental and social factors. Informed consent was obtained from all subjects. After performing standard 367 
sample QC we included 5,402 NFBC1966 participants that were genotyped on an Illumina HumanCNV370DUO 368 
Analysis BeadChip. 329,401 variants were included in the imputation scaffold. Variants were imputed to the HRC 369 
reference r1.1 2016 on the Michigan Imputation Server. Prior to analysis we excluded variants monomorphic in this 370 
dataset. In NFBC1966, we used a Vitalograph P-model spirometer (Vitalograph Ltd., Buckingham, UK), with a 371 
volumetric accuracy of ±2% or ±50 mL whichever was greater. The spirometer was calibrated regularly using a 1-Litre 372 
precision syringe. The spirometric manoeuvre was performed three times but was repeated if the coefficient of 373 
variation between two maximal readings was >4%. 374 
The Northern Finland Birth Cohort 1986 (NFBC1986) consists of 99% of all children, who were born in the provinces 375 
of Oulu and Lapland in Northern Finland between 1 July 1985 and 30 June 1986. 9,203 live-born individuals entered 376 
the study.25 At the age of 16, the subjects living in the original target area or in the capital area (n=9,215) were 377 
invited to participate in a follow-up study including a clinical examination. 7,344 participants attend the study in year 378 
2001/2002, of which 5,654 completed the postal questionnaire, the clinical examination and provided a blood 379 
sample.26 DNA was extracted from all 5,654 blood samples. An informed consent for the use of the data including 380 
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DNA was obtained from all subjects. After performing standard sample QC we included 3,743 NFBC1986 participants 381 
that were genotyped on an Illumina Human Omni Express Exome 8v1.2 BeadChip. 889,119 variants were included in 382 
the imputation scaffold. Variants were imputed to the HRC reference r1.1 2016 on the Michigan Imputation Server. 383 
For Spirometry measurements, we used a Vitalograph Gold Standard (Model 2150) (Vitalograph Ltd., Buckingham, 384 
UK). The machines were calibrated every day the medical examination took place. The spirometric manoeuvre was 385 
performed in an upright sitting position while wearing a nose clip. At least three acceptable manoeuvres were 386 
performed. Acceptable manoeuvers did not exceed a difference between two maximal FEV 1 and FVC values of 4 %. 387 
The results were recorded with a 0.05 litre accuracy. 388 
The Northern Sweden Population Health Study (NSPHS) represents a cross-sectional study conducted in the 389 
communities of Karesuando (samples gathered in 2006) and Soppero (2009) in the subarctic region of the County of 390 
Norrbotten, Sweden. Spirometry was performed in sitting position without noseclips using a MicroMedicalSpida 5 391 
spirometer (http://www. medisave.co.uk). Three consecutive 28 lung function measurements per participant were 392 
done and the maximum value per measured lung function parameter was used for further analysis. Relatedness was 393 
taken into account by applying the "polygenic" linear mixed effects model. Genome-wide association analysis was 394 
performed using a score test, a family-based association test27 which uses the residuals and the variance-covariance 395 
matrix from the polygenic model and the SNP fixed effect coded under an additive model. 396 
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based, cross-sectional study in the isolated 397 
Scottish archipelago of Orkney. Spirometry was performed in the sitting position without nose clips, using a Spida 398 
handheld spirometer. Measurements were repeated once and the better reading was used for analysis. 399 
The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS)28 is a population-based study of 400 
cardiovascular health in the elderly. Mailed invitations were sent to subjects who lived in Uppsala, Sweden, within 2 401 
months after their 70th birthday. The subjects were randomly selected from the community register. A total of 1,016 402 
men and women participated in the baseline investigation (participation rate, 50.1%). Spirometry was performed in 403 
901 subjects at baseline in accordance with American Thoracic Society recommendations (α spirometer; Vitalograph 404 
Ltd; Buckingham, UK). The best value from three recordings was used. The Ethics Committee of the University of 405 
Uppsala approved the study, and the participants gave their informed consent. Genotyping of all samples was 406 
undertaken using the Illumina Omni Express and CardioMetabochip. Genotypes were called using GENCALL. A total 407 
of 738,879 SNPs passed quality control (thresholds: call rate < 0.95, and call rate < 0.99 for MAF<5%; HWE P < 10-6). 408 
SNPs with MAF<1% were removed from the imputation scaffold. Imputation was performed using IMPUTE up to 409 
haplotypes from the Haplotype Reference Consortium. 410 
The SAPALDIA cohort is a population-based multi-center study in eight geographic areas representing the range of 411 
environmental, meteorological and socio-demographic conditions in Switzerland29,30. It was initiated in 1991 412 
(SAPALDIA 1) with a follow-up assessment in 2002 (SAPALDIA 2) and 2010 (SAPALDIA3). This study has specifically 413 
been designed to investigate longitudinally lung function, respiratory and cardiovascular health; to study and identify 414 
the associations of these health indicators with individual long term exposure to air pollution, other toxic inhalants, 415 
life style and molecular factors. 416 
The Study of Health In Pomerania (SHIP)31 is a cross-sectional and prospective longitudinal population-based cohort 417 
study in Western Pomerania assessing the prevalence and incidence of common diseases and their risk factors. SHIP 418 
encompasses the two independent cohorts SHIP and SHIP-TREND. A total of 4,308 participants were recruited 419 
between 1997 and 2001 in the SHIP cohort. Between 2008 and 2012 a total of 4,420 participants were recruited in 420 
the SHIP-TREND cohort. Individuals were invited to the SHIP study centre for a computer-assisted personal 421 
interviews and extensive physical examinations. 422 
The examinations for SHIP were conducted using a body plethysmograph equipped with a pneumotachograph 423 
(VIASYS Healthcare, JAEGER, Hoechberg, Germany) which meets the American Thoracic Society (ATS) criteria.32 The 424 
 14 
 
volume signal of the equipment was calibrated with a 3.0 litre syringe connected to the pneumotachograph in 425 
accordance with the manufacturer´s recommendations and at least once on each day´s testing. Barometric pressure, 426 
temperature and relative humidity were registered every morning. Calibration of reference gas and volume was 427 
examined under ATS-conditions (Ambient Temperature Pressure) and the integrated volumes were BTPS (Body 428 
Temperature Pressure Saturated) corrected.32,33 Lung function variables were measured continuously throughout the 429 
baseline breathing and the forced manoeuvres using a VIASYS HEALTHCARE system (MasterScreen Body/Diff.). 430 
Spirometry flow volume loops were conducted in accordance with ATS recommendations33 in a sitting position and 431 
with wearing nose clips. The participants performed at least three forced expiratory lung function manoeuvres in 432 
order to obtain a minimum of two acceptable and reproducible values.34 Immediate on-screen error codes indicating 433 
the major acceptability (including start, duration and end of test) and reproducibility criteria supported the attempt 434 
for standardised procedures. The procedure was continuously monitored by a physician. The best results for FVC, 435 
FEV1, peak expiratory flow (PEF) and expiratory flow at 75%, 50%, 25% of FVC (MEF 75, MEF 50, MEF 25) were taken. 436 
The ratio of FEV1 to FVC was calculated from the largest FEV1 and FVC. 437 
In terms of the pulmonary items the computer-assisted interview in SHIP-TREND was nearly identical to that of the 438 
SHIP. Of the 4.420 subjects who have been investigated in the study, 2.678 (60.6 %) of the subjects have undergone 439 
spirometry, body plethysmography, and measurements of diffusing capacity (CO and NO), IOS and respiratory 440 
muscle strength. In SHIP-TREND, the following additional methods that are of particular interest in terms of lung 441 
health and comorbidities have been applied: polysomnography, analysis of volatile compounds in the exhaled 442 
breath, and whole-body MRI. The following devices have been used for the pulmonary investigations in SHIP-TREND: 443 
a MasterScreen for body plethysmography, diffusing capacity measurements (single breath) and measurements of 444 
respiratory muscle strength (Viasys Healthcare, Hoechberg, Germany), an ABL 500 and later an ABL 80 for blood gas 445 
analyses (Radiometer, Copenhagen, Denmark), a MasterScreen PFT Pro CO-NO-Diffusion (CareFusion, Hoechberg, 446 
Germany), a MasterSreen IOS for Impuls-Oscillometry (CareFusion, Hoechberg, Germany), and a MicroCO carbon 447 
monoxide monitor (CareFusion, Hoechberg, Germany). 448 
The United Kingdom Household Longitudinal Study (UKHLS), also known as Understanding Society 449 
(https://www.understandingsociety.ac.uk) is a longitudinal panel survey of 40,000 UK households (England, 450 
Scotland, Wales and Northern Ireland) representative of the UK population. Participants are surveyed annually since 451 
2009 and contribute information relating to their socioeconomic circumstances, attitudes, and behaviours via a 452 
computer assisted interview. The study includes phenotypical data for a representative sample of participants for a 453 
wide range of social and economic indicators as well as a biological sample collection encompassing biometric, 454 
physiological, biochemical, and haematological measurements and self-reported medical history and medication 455 
use. The United Kingdom Household Longitudinal Study has been approved by the University of Essex Ethics 456 
Committee and informed consent was obtained from every participant. 457 
For a subset of individuals who took part in a nurse health assessment, blood samples were taken and genomic DNA 458 
extracted. Of these, 10,484 samples were genotyped at the Wellcome Trust Sanger Institute using the Illumina 459 
Infinium HumanCoreExome-12 v1.0BeadChip. 460 
Lung function measures in samples from England and Wales were conducted with the NDD Easy On-PC spirometer 461 
(NDD Medical Technologies, Zurich, Switzerland). Participants were excluded in the following cases: pregnancy, 462 
having had abdominal or chest surgery (past 3 weeks), admitted to the hospital with a heart complaint (in the past 6 463 
weeks), having had recent eye surgery (past 4 weeks), or in case of having a tracheostomy. Subjects were asked to 464 
perform up to 8 blows that ideally lasted at least 6 seconds, uninterrupted by coughing, glottis closure, laughing or 465 
leakage of air. Upon completion, the measurements were rated either acceptable or unacceptable by the NDD Easy 466 
On-PC software. 467 
The Viking Health Study - Shetland (VIKING) is a family-based, cross-sectional study that seeks to identify genetic 468 
factors influencing cardiovascular and other disease risk in the population isolate of the Shetland Isles in northern 469 
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Scotland. Genetic diversity in this population is decreased compared to Mainland Scotland, consistent with the high 470 
levels of endogamy historically.  Participants were recruited between 2013 and 2015, each having at least three 471 
grandparents from Shetland. Fasting blood samples were collected and over 300 health-related phenotypes and 472 
environmental exposures were measured in each individual. All participants gave informed consent and the study 473 
was approved by the South East Scotland Research Ethics Committee. 474 
The Young Finns Study (YFS) is a population-based follow up-study started in 198035. The main aim of the YFS is to 475 
determine the contribution made by childhood lifestyle, biological and psychological measures to the risk of 476 
cardiovascular diseases in adulthood. In 1980, over 3,500 children and adolescents all around Finland participated in 477 
the baseline study. The follow-up studies have been conducted mainly with 3-year intervals. The latest 30-year 478 
follow-up study was conducted in 2010-2011 (ages 33-49 years) with 2,063 participants. The study was approved by 479 
the local ethics committees (University Hospitals of Helsinki, Turku, Tampere, Kuopio and Oulu) and was conducted 480 
following the guidelines of the Declaration of Helsinki. All participants gave their written informed consent. 481 
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Study details 563 
Details of the COPDGene Study (NCT00608764, www.copdgene.org) have been previously described.36,37 Eligible 564 
subjects were of non-Hispanic white or African-American ancestry, aged 45-80 years old, with a minimum of 10 pack-565 
years of smoking and no lung disease (other than COPD or asthma). Moderate to severe COPD cases were defined 566 
using pre-bronchodilator % predicted FEV1 < 80% predicted and FEV1/FVC < 0.7. Genotyping was performed by 567 
Illumina (San Diego, CA) on the HumanOmniExpress array. Subjects were excluded for missingness, heterozygosity, 568 
chromosomal aberrations, sex check, population outliers, and cryptic relatedness. Genotyping at the Z and S alleles 569 
was performed in all subjects. Subjects known or found to have severe alpha-1 antitrypsin deficiency were excluded. 570 
Markers were excluded based on missingness, Hardy-Weinberg P-values, and low minor allele frequency. Imputation 571 
on the COPDGene cohorts was performed via the Michigan Imputation Server using minimac3 with the Haplotype 572 
Reference Consortium (HRC v1.1) reference panel.38 Variants with an r2 value of ≤ 0.3 were removed from further 573 
analysis.  574 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) 575 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE; SCO104960, NCT00292552, 576 
www.eclipse-copd.com): Details of the ECLIPSE study and genome-wide association analysis have been described 577 
previously.36,37 ECLIPSE was an observational 3-year study of COPD. Both cases and controls were aged 40-75 with at 578 
least a 10 pack-year smoking history without other respiratory diseases; cases were defined using pre-579 
bronchodilator % predicted FEV1 < 80% predicted and FEV1/FVC < 0.7, and controls had normal spirometry (% 580 
predicted FEV1 > 85%). Genotyping was performed using the Illumina HumanHap 550 V3 (Illumina, San Diego, CA). 581 
Subjects and markers with a call rate of < 95% were excluded. Population stratification exclusion and adjustment on 582 
self-reported white subjects was performed using EIGENSTRAT (EIGENSOFT Version 2.0). Imputation was performed 583 
via the Michigan Imputation Server using minimac3 with the Haplotype Reference Consortium (HRC v1.1) reference 584 
panel.38  585 
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National Emphysema Treatment Trial (NETT) and Normative Aging Study (NAS) (NETT/NAS) 586 
Details of the National Emphysema Treatment Trial have been described previously.39,40 NETT 587 
(www.nhlbi.nih.gov/health/prof/lung/nett/) was a multicentre clinical trial to evaluate lung volume reduction 588 
surgery. Enrolled subjects had severe airflow obstruction by pre-bronchodilator spirometry (% predicted FEV1 < 45%) 589 
and evidence of emphysema on computed tomography (CT) chest imaging; exclusion criteria included significant 590 
sputum production or bronchiectasis. A subset of 382 self-reported white subjects without severe alpha-1 591 
antitrypsin deficiency were enrolled in the NETT Genetics Ancillary Study.  592 
The Normative Aging Study is a longitudinal study of healthy men established in 1963 and conducted by the Veterans 593 
Administration (VA).39,41 Men aged 21 to 80 years from the greater Boston area, free of known chronic medical 594 
conditions, were enrolled. Smoking controls were of self-reported white ancestry and at least 10 pack-years of 595 
cigarette smoking with no evidence of airflow obstruction on spirometry on their most recent visit. Genotyping for 596 
NETT-NAS was performed using the Illumina Quad 610 array (Illumina, San Diego, CA), with quality control, 597 
population stratification adjustment, as described previously. Imputation was performed via the Michigan 598 
Imputation Server using minimac3 with the Haplotype Reference Consortium (HRC v1.1) reference panel.38  599 
NORWAY-GenKOLS 600 
Details on the Norwegian GenKOLS (Genetics of Chronic Obstructive Lung Disease, GSK code RES11080) study have 601 
been described previously.42 Subjects with > 2.5 pack years of smoking history were recruited from Bergen, Norway; 602 
cases had pre-bronchodilator % predicted FEV1 < 80% predicted and FEV1/FVC < 0.7, while controls had normal 603 
spirometry; subjects with severe alpha-1 antitrypsin deficiency and other lung diseases (aside from asthma) were 604 
excluded. Genotyping was performed using Illumina HumanHap 550 arrays (Illumina, San Diego, CA), with quality 605 
control, population stratification adjustment as previously described. Imputation was performed via the Michigan 606 
Imputation Server using minimac3 with the Haplotype Reference Consortium (HRC v1.1) reference panel.38  607 
SPIROMICS 608 
SPIROMICS is a prospective cohort study that enrolled 2,981 participants with the goals of identifying new COPD 609 
subgroups and intermediate markers of disease progression.43,44 SPIROMICS is a well-characterized longitudinal 610 
cohort with comprehensive phenotyping including measurements of lung function and quantitative CT scan. 611 
Spirometry was performed before and after four inhalations with 90 µg albuterol and 18 µg ipratropium per 612 
inhalation according to ATS recommendations. Participants were recruited at each center through physician referral, 613 
advertisement in clinical areas or self-referral using the SPIROMICS study website (www.spiromics.com). The 614 
research protocol was approved by the institutional review boards of all participating institutions with written 615 
informed consent from all participants. In this study, non-Hispanic White smokers (ever or current smoking≥20 616 
packs/year) with genotyping information available were included in this analysis. Smokers with COPD (n=988) were 617 
defined as smokers (smoking≥20 packs/year) with post-bronchodilator FEV1/FVC<0.7 and FEV1<0.8 (GOLD stage 2-4) 618 
and ‘healthy’ smoking controls (n=537) were defined as smokers (smoking≥20 packs/year) with post-bronchodilator 619 
FEV1/FVC≥0.7 (GOLD stage 0). Details of genome-wide association analysis has been described previously.45 In brief, 620 
DNA was isolated using standard protocols, and SNP genotyping performed using Illumina 621 
HumanOmniExpressExome BeadChip and BeadStudio (Illumina, Inc., San Diego, CA). Imputation was performed on 622 
the basis of reference panel of HRC r1.1 2016 using Michigan Imputation Sever 623 
(https://imputationserver.sph.umich.edu). Genetic association analysis was performed using PLINK software 624 
(http://zzz.bwh.harvard.edu/plink/). 625 
EXCEED Cohort 626 
The Extended Cohort for E-health, Environment and DNA (EXCEED) is was set up to develop understanding of the 627 
genetic, environmental and lifestyle-related causes of health and disease (cohort profile currently in preparation). 628 
Participants were recruited primarily through local general practices in Leicester City, Leicestershire and Rutland, 629 
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with 9,840 participants recruited to date. Baseline data collection included a lifestyle questionnaire, anthropometry 630 
measurements, and for approximately half of the participants, spirometry. The correlation between height and lung 631 
function (FEV1, FVC and FEV1/FVC) was calculated in R using Pearson's correlation.  632 
 20 
 
Supplementary Figures 633 
Supplementary Figure 1: 6 ethnic grouping clusters chosen by K-means clustering 634 
1. K-means clustering was performed on the first 2 principal components. 6 clusters were chosen to infer ancestry 635 
groupings. The black dots show the cluster centres. 636 
 637 
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2. Correlation between ancestry groups derived from K-means clustering and self-reported ethnicity; the numbers 638 
of samples in each K-means cluster (y-axis) with each self-reported ethnicity (x-axis) are shown. 639 
640 
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Supplementary Figure 2: Manhattan plots 641 
1. P values are from the meta-analysis of UK Biobank and SpiroMeta. Novel signals are labelled in black (Tier 1 in bold); previously reported signals are labelled in blue. 642 
The red line is P=5×10-9. 643 
 644 
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 647 
  648 
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Supplementary Figure 3: Assessment of previously reported signals 649 
Description of assessment of 184 signals for lung function or COPD previously reported in the literature. Signals were pruned for independence, leaving 157 signals. 650 
Corroboration of association was found for 142/157 signals. 2/142 signals were known to be associated with smoking behaviour, and in the current study, we replicated 651 
these findings, and also showed no association in non-smokers. After removing these signals, 140 remained for assessment. After combining with 139 novel signals, 279 652 
signals entered downstream analyses. 653 
*=Wilk et al. 2009 [PMID: 19300500];46 Hancock et al. 2010 [PMID: 20010835];47 Repapi et al. 2010 [PMID: 20010834];48 Soler Artigas et al. 2011 [PMID: 21946350];49 Cho et 654 
al. 2012 [PMID: 22080838];50 Loth et al. 2014 [PMID: 24929828];51 Lutz et al. 2015 [PMID: 26634245];52 Soler Artigas et al. 2015 [PMID: 21946350];53 Wain et al. 2015 655 
[PMID: 28166213];2 Hobbs et al. 2016 [PMID: 26771213];54 Hobbs et al. 2017 [PMID: 28166215];55 Wain et al. 2017 [PMID: 26423011];56 Wyss et al. 2017 656 
[https://www.biorxiv.org/content/early/2017/10/05/196048]57; Jackson et al. 2018 [https://wellcomeopenresearch.org/articles/3-4/v1];58 657 
**=Wyss et al. 2017 [https://www.biorxiv.org/content/early/2017/10/05/196048]57 658 
†=See Wain et al. 2017 [PMID: 28166213] for details of HLA independence analysis.56 659 
‡=Lutz et al. 2015 [PMID: 26634245];52 Cho et al. 2012 [PMID: 22080838]50 660 
Figure on next page. 661 
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Supplementary Figure 4: Tissue-specific enrichment of overlap with DNase I hotspots with GARFIELD 663 
The wheel plots display functional enrichment for associations with A) FEV1/FVC and B) FVC within DNase I 664 
hypersensitivity site hotspot regions in the ENCODE and Roadmap Epigenomics project. The radial axis shows 665 
fold enrichment calculated at P<5 x 10-5 and P<5 x 10-9 for each of the 424 cell lines tested (derived from 55 666 
different tissues). Cell lines are sorted by tissue, represented along the outside edge of the plot with font size  667 
proportional to the number of cell lines from that tissue. Fold enrichment values at the different thresholds are 668 
plotted with different colours inside the plot (e.g. values at P< 5×10−9 are in black). If present, the dots along the 669 
inside edge of the plot denote significant enrichment for a given cell line at Bonferroni-adjusted P<0.05 (for 424 670 
tests; P≈1x10-4), with the dot at the outer edge of plot corresponding to SNPs with GWAS P<5x10 -5 used as input, 671 
and the innermost dot corresponding to SNPs with GWAS P<5x10 -9. 672 
1. Enrichment of overlap of SNPs associated with FEV1/FVC with DNase I hotspots 673 
 674 
  675 
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2. Enrichment of overlap of SNPs associated with FVC with DNase I hotspots 676 
 677 
  678 
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Supplementary Figure 5: Comparison of genetic effects for height and lung function. 679 
Height effect look up in meta-analysis of GIANT59 and UK Biobank for 76/85 signals associated with height in the 680 
PheWAS (9 had no proxies at r2>0.4),plotted against lung function effect in A) UK Biobank and B) SpiroMeta. All traits 681 
are rank inverse-normal transformed (Z-score). The Pearson correlation r is shown with the P value for the null 682 
hypothesis r = 0. 683 
A) GIANT + UK Biobank meta-analysis height effect vs. UK Biobank lung function effect 684 
 685 
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B) GIANT  + UK Biobank meta-analysis height effect vs. SpiroMeta lung function effect  686 
 687 
9/85 SNPs for which there was no proxy with r2 > 0.4 in GIANT: rs141942982, rs7838717, rs10998018, rs2812208, 688 
rs56383987, rs62070648, rs77672322, rs34093919, rs9274247 689 
 690 
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Supplementary Figure 6: Comparison of effect sizes after excluding asthma samples 
Comparison of effects (inverse-normal rank-transformed Z-scores) in UK Biobank for 139 novel and 140 previously reported signals in all UK Biobank samples with lung 
function data (x-axis, N=321,047) and after excluding 37,868 samples with doctor diagnosed asthma (y-axis, N=283,179). Doctor diagnosed asthma is self-reported 
touchscreen answer (UK Biobank field ID: 6152). 
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Supplementary Figure 7: Power calculations 
Power to detect a range of single variant effect sizes, as standard deviations (SDs) of the continuous lung function 
phenotypes (FEV1, FVC, FEV1/FVC or PEF), over a range of minor allele frequencies (MAF). 
1. Power to meet tier 1 and tier 2 criterion P<10-3 in SpiroMeta (n=79,055) 
 
2. Power for association of previous signals P<10-5 in UK Biobank (n=321,047) 
 34 
 
  
 35 
 
Supplementary Figure 8: QQ plots 
LD score regression implemented in LDSC5,60 was used to estimate inflation of test statistics due to confounding. The 
unadjusted genomic inflation factors λ are shown as well as the LD score regression intercept which is the inflation 
factor adjusted for polygenicity. Genomic control was applied if the LD score regression intercept was larger than 
1.05 suggesting residual inflation. Accordingly, genomic control was applied to UK Biobank but not SpiroMeta. 
UK Biobank 
 
 
SpiroMeta 
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Supplementary Figure 9: Meta-analysis of 279 variants in five independent cohorts for association with COPD. 
Single-variant results for all 279 variants included in the genetic risk score were obtained from five external study groups of European-descent (COPDGene, GenKOLS, 
ECLIPSE, NETT-NAS, and SPIROMICS). These results were meta-analysed using a fixed-effect model, and are presented in the follow panels (ordered in genomic order, from 
chromosomes 1-22). Abbreviations: LCI/UCI=lower/upper bound of 95% confidence interval, I2=value for I2-statistic for heterogenetity. Grey boxes represent odds ratios for 
COPD per 1-allele increase in the FEV1/FVC lowering allele. Black horizontal bars denote the 95% confidence interval. 
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Supplementary Figure 10: Individual PheWAS results, separately by trait category 
In these extended plots, individual associations passing FDR 1% between the 279 lung function signals and 2411 traits are shown. The y-axis is a signed log10(FDR) i.e. 
where a positive SNP-trait association is associated with the FEV1/FVC decreasing allele, the log10(FDR) is given a positive sign, and where the SNP trait association is 
negative, the log10(FDR) is given a negative sign. Each category has its own separate subplot. Categories are presented in order of their most significant (according to FDR) 
association, and within each subplot, results for each trait are presented in decreasing order of FDR. Triangular points indicate quantitative traits, and circular points 
indicate binary traits. For each category, associations that are >50% of the highest absolute log10(FDR) value are labelled with their rsID. Individual SNP results for 
associations passing an FDR of 1% (along with details of their categorisation, and the plain English labels used in Figure 4 of the main manuscript) are available in 
Supplementary Table 23. Due to the size of the full PheWAS data set, individual results of the 279*2411 SNP-trait associations are available from the authors on request. 
 43 
 
 
 44 
 
 
 45 
 
 
 46 
 
 
 47 
 
 
 48 
 
 
 49 
 
 
 50 
 
  
 51 
 
Supplementary Tables 
Supplementary Table 1: UK Biobank demographics 
Demographic information for UK Biobank samples of European ancestry used in discovery. 
 All Females Males 
N Total 321,047 178,489 142,558 
Age range (y) at lung function measurement 39-72 39-71 39-72 
Mean age, y (s.d.) 56.44 (8.02) 56.24 (7.92) 56.70 (8.12) 
Mean height, cm (s.d.) 168.57 (9.13) 162.77 (6.18) 175.83 (6.70) 
Mean FEV1, L (s.d.) 2.84 (0.76) 2.44 (0.52) 3.34 (0.72) 
Mean FVC, L (s.d.) 3.74 (0.96) 3.18 (0.62) 4.43 (0.86) 
Mean FEV1/FVC (s.d.) 0.76 (0.06) 0.77 (0.06) 0.75 (0.07) 
Mean PEF, L/min (s.d.) 406.19 (117.55) 342.12 (74.96) 486.40 (111.84) 
N never smokers 173,658 106,298 67,360 
N ever smokers 147,389 72,191 75,198 
UK BiLEVE array 49,107 24,566 24,541 
UK Biobank array 271,940 153,923 118,017 
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Supplementary Table 2: SpiroMeta Studies 
B58C (B58C-T1DGC, British 1958 Birth Cohort–Type 1 Diabetes Genetics Consortium; B58C-GABRIEL British 1958 Birth Cohort–GABRIEL consortium; B58C-WTCCC, British 
1958 Birth Cohort–Wellcome Trust Case Control Consortium); BHS1&2, Busselton Health Study 1 and 2; the CROATIA- Korcula study; the CROATIA-Split study; the CROATIA-
Vis study; EPIC population based, European Prospective Investigation into Cancer and Nutrition Cohort; GS:SFHS, Generation Scotland: Scottish Family Health Study; H2000, 
Finnish Health 2000 survey; KORA F4, Cooperative Health Research in the Region of Augsburg; KORA S3, Cooperative Health Research in the Region of Augsburg; LBC1936, 
Lothian Birth Cohort 1936; NFBC1966, Northern Finland Birth Cohort of 1966; NFBC1966, Northern Finland Birth Cohort of 1986; NSPHS, Northern Sweden Population 
Health Study; ORCADES, Orkney Complex Disease Study; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; SHIP, Study of Health in Pomerania; SHIP-
TREND; UKHLS; VIKING; YFS, the Young Finish Study. The total size in this table is not exactly equal to the maximum sample size given in the main text, since some studies 
had subtly different subsets of individuals entering each of the four lung function trait GWAS. 
Study name N Total 
N 
male 
N 
female 
Age range 
(y) at lung 
function 
measureme
nt 
Mean age, y 
(s.d.) 
Mean height, 
cm (s.d.) 
Mean FEV1, 
L (s.d.) 
Mean FVC, L 
(s.d.) 
Mean 
FEV1/FVC 
(s.d.) 
Mean PEF, 
L/min (s.d.) 
N never 
smokers 
N ever 
smokers 
Genotyping Platform 
Imputation 
Panel 
B58C 5934 2955 2979 44-45 45.12 (0.38) 169.43 (9.29) 3.30 (0.76) 4.19 (0.98) 0.79 (0.08) -- 1709 4225 Illumina 550k/610k 1000G 
BHS1&2 4355 1922 2433 17-97 51.21 (17.00) 168.00 (9.39) 3.01 (0.96) 3.88 (1.16) 0.77 (0.07) -- 2301 2054 
Illumina 610-Quad (N=1,168 )  
& Illumina 660W-Quad 
(N=3,428 ) 
1000G 
CROATIA-Korcula 826 302 524 18-90 55.63 (13.50) 168.10 (9.20) 2.72 (0.83) 3.29 (0.96) 0.83 (0.1) -- 403 423 
Illumina HumanHap370CNV 
duo chip 
1000G 
CROATIA-Split 493 210 283 18-85 49.08 (14.63) 172.60 (9.49) 3.19 (0.91) 3.80 (1.06) 0.84 (0.08) -- 239 254 
Illumina HumanHap370CNV 
quad chip 
1000G 
CROATIA-Vis 925 390 535 18-88 55.90 (15.51) 167.80 (9.88) 3.42 (1.21) 4.41 (1.42) 0.77 (0.09) -- 388 537 
Illumina Infinium 
HumanHap300 BeadChip 
1000G 
EPIC population 
based 
20771 9664 11107 39-79 59.1 (9.27) 167.1 (9.08) 2.51 (0.74) 3.06 (0.93) 0.83 (0.11) 364.07 (123.16) 9532 11239 Affymetrix UKBioBank Axiom HRC 
GS:SFHS 16048 6633 10415 18-99 46.87 (14.6) 168.4 (9.50) 2.97 (0.88) 3.88 (1.00) 0.76 (0.11) -- 8581 7467 Illumina OmniExpress+Exome HRC 
H2000 821 394 427 30-75 50.47 (10.91) 169.10 (9.14) 3.29 (0.9) 4.16 (1.07) 0.79 (0.07) -- 249 572 Illumina HumanHap 610K 1000G 
KORA F4 1474 717 757 41-84 55.08 (9.90) 169.15 (9.42) 3.23 (0.85) 4.19 (1.05) 0.77 (0.07) -- 556 918 Affymetrix Axiom 1000G 
KORA S3 1147 551 596 28-89 50.82 (15.23) 169.22 (9.32) 3.34 (0.90) 4.10 (1.06) 0.81 (0.08) -- 520 627 
Illumina Omni 2.5/ 
Illumina Omni Express 
1000G 
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Study name N Total 
N 
male 
N 
female 
Age range 
(y) at lung 
function 
measureme
nt 
Mean age, y 
(s.d.) 
Mean height, 
cm (s.d.) 
Mean FEV1, 
L (s.d.) 
Mean FVC, L 
(s.d.) 
Mean 
FEV1/FVC 
(s.d.) 
Mean PEF, 
L/min (s.d.) 
N never 
smokers 
N ever 
smokers 
Genotyping Platform 
Imputation 
Panel 
LBC1936 991 501 490 68-71 69.55 (0.84) 166.44 (8.93) 2.38 (0.67) 3.04 (0.87) 0.79 (0.10) -- 437 554 Illumina 610-Quadv1 1000G 
NFBC1966 5078 2417 2661 30-32 31.15 (0.35) 171.24 (9.09) 3.95 (0.79) 4.72 (0.99) 0.84 (0.06) -- 2478 2600 
Illumina HumanCNV‐370DUO 
Analysis BeadChip 
HRC 
NFBC1986 3210 1516 1694 14-16 16.01 (0.37) 169.34 (8.43) 3.78 (0.70) 4.31 (0.85) 0.88 (0.08) -- 2476 734 
Illumina Human Omni Express 
Exome 8v1.2 
HRC 
NSPHS 871 400 471 14-91 49.20 (20.00) 164.00 (10.10) 2.92 (0.90) 3.53 (1.06) 0.83 (0.09) -- 750 121 
Illumina Infinum HapMap 300 
v2 & Illumina Human 
OmniExpress 
1000G 
ORCADES 1802 719 1083 16-91 54.00 (15.00) 166.00 (9.20) 2.89 (0.83) 3.61 (0.99) 0.79 (0.08) -- 1022 780 
Illumina Hap300, Illumina 
Omni1 & Illumina OmniX 
1000G 
PIVUS 806 395 411 69-72 70.20 (0.176) 169.09 (9.208) 2.45 (0.680) 3.23 (0.869) 0.764 (0.103) -- 393 413 
Illumina OmniExpress and 
Metabochip 
HRC 
SAPALDIA 1378 665 713 18-61 41.30 (11.20) 169.47 (9.12) 3.53 (0.86) 4.50 (1.04) 0.78 (0.08) -- 631 747 Illumina 610k quad 1000G 
SHIP 1759 860 899 20-80 47.17 (13.67) 169.7 (9.13) 3.28 (0.89) 3.87 (1.03) 0.85 (0.06) 437.58 (125.17) 818 941 Affymetrix SNP 6.0 HRC 
SHIP-TREND 804 363 441 21-81 51.24 (13.34) 169.9 (9.00) 3.29 (0.87) 4.14 (1.06) 0.80 (0.06) 392.82 (125.91) 342 462 Illumina Human Omni 2.5 HRC 
UKHLS 7442 3290 4152 16-99 53.11 (15.94) 167.7 (9.45) 2.84 (0.90) 3.83 (1.09) 0.75 (0.09) -- 2938 4504 Illumina CoreExome v1.0 HRC 
VIKING 1701 672 1029 18-91 50.72 (14.97) 168 (0.09) 3.07 (0.81) 4.02 (0.96) 0.76 (0.09) 450.08 (130.14) 943 757 Illumina OmniExpress Exome HRC 
YFS 419 198 221 30-47 38.88 (5.07) 172.25 (8.90) 3.73 (0.75) 4.68 (0.99) 0.8 (0.06) -- 233 186 Illumina 670k custom 1000G 
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Supplementary Table 3: SpiroMeta analysis method 
Study name 
Individual 
call rate filter 
(applied 
before 
imp’n) 
SNP call rate 
filter 
(applied 
before 
imp’n) 
SNP HWE P filter 
(applied before 
imp’n) 
SNP MAF 
filter 
(applied 
before 
imp’n) 
Other filters 
No of SNPs after 
filtering (before imp’n) 
Imputation software 
and version 
Reference panel used for 
imp’n 
Genotype-
phenotype 
association 
software 
B58C None >=95% 
≥0.0001 (tested 
on females only 
for chromosome 
X) 
≥1% 
Consistent allele frequencies across 
data deposits (P≥0.0001 for pairwise 
comparisons) and for chrX SNPs, 
consistent allele frequencies between 
males and females (P≥0.0001). 
500,521 (including 
11,696 chrX) 
MACH 1.0.18 & 
Minimac 2012-11-16 
1000 Genomes Phase 1 
March 2012 
probABEL 
0.1-9e 
BHS1&2 0.95 0.95 1.00E-06 0.01 
Individuals were removed if they had 
sex inconsistencies,  had 
heterozygosity >5 s.d. from the mean, 
were PCA outliers, were 1 individual 
from a pair of duplicates or had IBD 
inconsistencies. 
521,307 
Minimac and MACH1 
v1.0.18 
b37; 1000 Genomes Phase 
1 March 2012 
ProbABEL 
CROATIA-
Korcula 
97% 98% 1.00E-06 0.01   316,879 SHAPEIT2, IMPUTE2 
b37; ALL (1000 Genomes 
Phase 1 integrated release 
v3, April 2012) 
ProbABEL 
CROATIA-
Split 
97% 98% 1.00E-06 0.01   321,727 SHAPEIT2, IMPUTE2 
b37; ALL (1000 Genomes 
Phase 1 integrated release 
v3, April 2012) 
ProbABEL 
CROATIA-Vis 97% 98% 1.00E-06 0.01   273,671 SHAPEIT2, IMPUTE2 
b37; ALL (1000 Genomes 
Phase 1 integrated release 
v3, April 2012) 
ProbABEL 
EPIC 
population 
based 
None 95% 1.00E-08 
Per-plate 
basis 
Monomorphic SNPs; chr 23-26; 
INDELS; monomorphic; call rate<95%; 
chr-pos-allels duplicates;  delta-AF > 
0.2; delta_AF>0.1 if MAF<0.01. Oxford 
QC:) exclude SNPs if not in HRC ref (no 
INDEL in HRC ref); 2) exclude if don’t 
match on chr-pos-allele; 3) strand 
check and flip; 4) exclude if delta-
AF>0.2; 5) exclude A/T and G/C SNPs 
with MAF>0.4 in ref; 6) exclude if chr-
pos duplicates 
708,715 
SHAPEIT v2.r790, 
Oxford 
HRC v1.0, 1000 Genomes 
p3 
BOLT-LMM 
v2.2 
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Study name 
Individual 
call rate filter 
(applied 
before 
imp’n) 
SNP call rate 
filter 
(applied 
before 
imp’n) 
SNP HWE P filter 
(applied before 
imp’n) 
SNP MAF 
filter 
(applied 
before 
imp’n) 
Other filters 
No of SNPs after 
filtering (before imp’n) 
Imputation software 
and version 
Reference panel used for 
imp’n 
Genotype-
phenotype 
association 
software 
GS:SFHS 97% 98% 1.00E-06 0.01 
Genetic ancestry outliers; 
monomorphic SNPs; high 
heterozygosity 
602,451 
SHAPEIT2 v2.r837, 
Sanger 
HRC panel v1.1, European REGSCAN 
H2000 0.95 
0.95 (0.99 for 
SNPs with 
MAF < 0.05) 
1.00E-06 0.01   
553,722 
 IMPUTE version 2.2.2 
1,000 Genomes 
haplotypes -- Phase I 
integrated variant set 
release (v3) in NCBI build 
37 (hg19) coordinates  
SNPTest 
KORA F4 0.97 0.98 5x10-6 0.01 
 -mismatch of phenotypic and genetic 
gender 
- 5s.d. from mean heterozygosity rate  
 - check for European ancestry  
 - check for population outlier  
523,260 (chr 1-26) 
508,532 (chr 1-22) 
14,096(chrX-nonPAR) 
444(chrX-PAR1) 
58(chrX-PAR2) 
SHAPEIT v2, IMPUTE 
v2.3.0 
1000g phase1 all 
(ALL_1000G_phase1integr
ated_v3_impute_mac1) 
SNPTEST 
v2.4.1 
KORA S3 0.97 0.98 5x10-6 0.01 
person wise: -mismatch of phenotypic 
and genetic gender 
- 5s.d. from mean heterozygosity rate  
 - check for European ancestry  
 - check for population outlier  
 SNP wise: only SNPs that were 
genotyped with good quality on both 
chips 
600641 (chr 1-26) 
588307 (chr 1-22) 
14625 (chrX-nonPAR) 
SHAPEIT v2, IMPUTE 
v2.3.0 
1000g phase1 all 
(ALL_1000G_phase1integr
ated_v3_impute_mac1) 
SNPTEST 
v2.4.1 
LBC1936 0.95 0.98 ≥0.001 0.01   549,692 minimac 2012-11-16 
1000 Genomes version 3, 
cosmopolitan 
mach2qtl 
NFBC1966 0.95 0.95 1.00E-04 0.01 
Genetic ancestry outliers; 
monomorphic SNPs; high 
heterozygosity; Gender mismatch; 0 
genetic sex; high heterozygosity; high 
relatedness 
364,535 Eagle v2.3, Michigan HRC r1.1 2016, European rvtests 
NFBC1986 0.99 0.99 1.00E-04 0.01 
Genetic ancestry outliers; 
monomorphic SNPs; high 
heterozygosity; Gender mismatch; high 
heterozygosity; high relatedness 
889,119 Eagle v2.3, Michigan HRC r1.1 2016, European rvtests 
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Study name 
Individual 
call rate filter 
(applied 
before 
imp’n) 
SNP call rate 
filter 
(applied 
before 
imp’n) 
SNP HWE P filter 
(applied before 
imp’n) 
SNP MAF 
filter 
(applied 
before 
imp’n) 
Other filters 
No of SNPs after 
filtering (before imp’n) 
Imputation software 
and version 
Reference panel used for 
imp’n 
Genotype-
phenotype 
association 
software 
NSPHS  0.9 0.95 
3.2E-08 (Infinum) 
& 1.4E-08 
(OmniExpress) 
0.01 FDR level of heterozygosity 0.01 
306,086 (Infinum) & 
631503 (OmniExpress) 
Impute2 (v 2.2.2) hg19, 1000 Genomes ProbABEL 
ORCADES 98% 97% 1.00E-06 
1% 
(Hap300) & 
monomorp
hic (Omni 
& OmniX) 
Subject Heterozygosity FDR<1% 
287,208 (Hap300), 
843723 (Omni)  & 
654651 (OmniX) 
shapeit.v2.r644.+imput
e_v2.2.2_x86_64_static
/impute2  
1000G Phase I Integrated 
Release Version 3 
Haplotypes (2010-11 data 
freeze, 2012-03-14 
haplotypes). 
probABEL v. 
0.4.3 
PIVUS 0.95 
0.95 (0.99 if 
MAF<0.05) 
1.00E-06 0.01 
Genetic ancestry outliers; 
monomorphic SNPs; >3SD from mean 
for heterozygosity, pi-hat>0.125, 
gender discordance 
738,583 SHAPEITv2, Oxford HRC v1.1, all SNPTEST v2.5 
SAPALDIA 95% 95% 1.00E-06 0.01 none 545,131 
Mach 1.0.16.a, 
minimac-omp RELEASE 
STAMP 2012-05-29 
(autosomes) & MiniMac 
RELEASE STAMP 2012-
11-16 (chr X) 
build37, 1000 Genomes probABEL 
SHIP 0.92 0.95 1.00E-04 None 
Genetic ancestry outliers; gender 
mismatch; pi-hat>0.25; monomorphic 
SNPS 
760,787 Eagle v2.3, Michigan 
HRC v1.1 reference, 
European 
Rvtests 
SHIP-TREND 0.94 0.95 1.00E-04 None 
Genetic ancestry outliers; gender 
mismatch; pi-hat>0.25; monomorphic 
SNPS 
1,691,610 Eagle v2.3, Michigan 
HRC v1.1 reference, 
European 
Rvtests 
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Study name 
Individual 
call rate filter 
(applied 
before 
imp’n) 
SNP call rate 
filter 
(applied 
before 
imp’n) 
SNP HWE P filter 
(applied before 
imp’n) 
SNP MAF 
filter 
(applied 
before 
imp’n) 
Other filters 
No of SNPs after 
filtering (before imp’n) 
Imputation software 
and version 
Reference panel used for 
imp’n 
Genotype-
phenotype 
association 
software 
UKHLS 0.98 0.98 1.00E-04 None 
Genetic ancestry, monomorphic SNPs, 
heterozygosity 3sd <>mean -visualised 
at 2 different MAF bins (≥1% and <1%); 
PI_HAT 0.2; Cluster separation score 
<0.4; sex check, ethnicity duplicates, 
withdrawn consent. Pre-imputation 
variants excluded that were: 
monomorphic, indels, differed to HRC 
in terms of strand, alleles, allele 
frequency (>0.2), A/T & G/C SNPs if 
MAF >0.4 and not in reference panel. 
357,230 
 
Autosomes: Eagle v2.3; 
ChrX: Shapeit v2.r790, 
Michigan 
Autosomes: HRC r1.1 
2016; ChrX: HRC r1.1 
2017, European 
SNPTEST v2.5 
VIKING 0.97 0.98 1.00E-06 
MAF>0.01 
for OMNI 
markers; 
MAF>0.000
1 for 
Exome 
Chip 
markers 
Genetic ancestry outliers; 
monomorphic SNPs; Duplicates and 
siblings 
668,762 
shapeit2r837 + 
duohmm; PBWT Sanger 
HRC v1.1, European REGSCAN 0.4 
YFS 0.95 0.95 1.00E-06 0.01 heterozygosity, relatedness 546,674 
SHAPEIT v1 and IMPUTE 
v2.2.2 
1000 Genomes Phase 1, 
release v3, March 2012 
haplotypes 
SNPTEST 
v.2.4.1 
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Supplementary Table 4: 139 novel signals 
See Excel spreadsheet. 
139 independent (r2<0.1) novel signals of association with lung function (99 tier 1, 40 tier 2): tier 1 signals meet the 
criteria P<5×10-9 in UK Biobank and P<10-3 in SpiroMeta; tier 2 signals meet the criteria P<5×10-9 in the meta-analysis 
and P<10-3 in both UK Biobank and SpiroMeta. UK Biobank p values have genomic control applied using the LD score 
regression intercept as the inflation factor (Supplementary Table 27). No genomic control was applied to SpiroMeta 
and the meta-analysis as there was no significant inflation after LD score regression. The allele frequencies and 
individual variant sample sizes for SpiroMeta were calculated based on a working total sample size of 83,118. For 
two secondary signals (rs10874851 and rs4796334) the association results are from a conditional analysis (no 
genomic control) where the primary signal is shown in the “conditioned on” column. Direction of effect is consistent 
for all signals. 
Supplementary Table 5: Tier 3 signals 
See Excel spreadsheet. 
Signals that reached P<5×10-9 in UK Biobank or the meta-analysis of UK Biobank and SpiroMeta, with consistent 
directions of effect but did not meet P<10-3 in SpiroMeta required to qualify as a Tier 2 signal. 
Supplementary Table 6: Association with smoking behaviour 
See Excel spreadsheet. 
Look up of smoking behaviour for 139 novel signals and 142 previously reported signals associated with lung 
function in this study. Also show are: lung function association results from the UK Biobank and SpiroMeta meta-
analysis. Bold P value for Smoking initiation (SI) or Cigarettes per day (CPD) indicates association with smoking 
behaviour P<1.8×10-4 (Bonferroni threshold for 281 tests). 
Supplementary Table 7: Smoking interaction 
See Excel spreadsheet. 
Results from stratified analyses of ever / never smokers in UK Biobank, SpiroMeta and a fixed-effects meta-analysis 
of the two. Evidence of interaction between ever and never smokers was sought by conducting a Welch test on the 
results of the stratified meta-analysis. A Bonferroni threshold of 1.79x10-4 (p=0.05/279 tests) was used. 
Supplementary Table 8: Previously reported signals 
See Excel spreadsheet. 
185 signals previously reported for lung function or COPD. For inclusion with our 139 novel signals in downstream 
analyses we first removed 24 non-independent (r2>0.1) signals from a recent GWAS of lung function. We also 
removed 3/6 HLA signals that were not independent, as established in one of our previous publications56. We then 
selected a subset of 142 signals that showed evidence of association in this study (UK Biobank P in bold): P<5×10-5 in 
321,047 UK Biobank samples for any lung function phenotype, either for the reported sentinel or a proxy with r2>0.5, 
or if one of our Tier 1 or 2 signals is in LD r2>0.1 with the previously reported sentinel. In downstream analyses, we 
excluded two signals (15q25 and CYP2A6, which have previously been reported to be associated with smoking 
behaviour, but are not associated with lung function in never smokers in the present study. This left 140 previously 
reported signals for inclusion in our final set of signals for downstream analyses Where PubMed ID (PMID) is missing, 
the variants are currently reported on bioRxiv57. 
Supplementary Table 9: Results for 279 lung function signals for all 4 traits 
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See Excel spreadsheet. 
Results from the meta-analysis of UK Biobank and SpiroMeta for all 279 reported lung function signals for each of 
the lung function quantitative traits FEV1, FVC, FEV1/FVC and PEF. 
Supplementary Table 10: Bayesian 99% credible sets 
See Excel spreadsheet. 
Bayesian 99% credible sets calculated using Wakefield’s method61 for 276 signals: 139 novel and 137 of 140 
previously reported showing significant association in this study (3 HLA signals excluded; Supplementary Table 8). 
Effect sizes and standard errors for the credible set calculation are from the meta-analysis of UK Biobank and 
SpiroMeta; variants with r2>0.4 with the sentinel and P<10-4 are included in the calculation the prior probability 
parameter W is 0.04. For previously reported signals we used the sentinel variant from the meta-analysis of UK 
Biobank and SpiroMeta in this study. 182 signals have the sentinel with the (joint) highest posterior probability (109 
novel, 73 previous); 20 signals have only the sentinel in the credible set (12 novel, 8 previous); 8 signals do not 
contain the sentinel in the credible set. Individual regions for all of these 276 signals are available to download as a 
separate file. 
Supplementary Table 11: Functional annotation of coding variants in the 99% credible sets 
See Excel spreadsheet. 
Variants that entered the functional annotation were those annotated as “exonic”, “splicing”, “ncRNA_exonic”, “5’ 
UTR” or “3’ UTR” (untranslated region) by ANNOVAR.  Annotation software used: SIFT, PolyPhen-2 and FATHMM all 
annotate missense variants, and CADD annotates non-coding variation. Variant annotated as deleterious (1) versus 
not (0) if the variant was labelled 'deleterious' by SIFT, 'probably damaging' or 'possibly damaging' by PolyPhen-2, if 
it had a CADD scaled score ≥20, or was annotated as “damaging” by FATHMM. See also Online Methods. Column 
explanations: All=harmful according to at least one of CADD, SIFT, PolyPhen-2, FATHMM; Post Prob=posterior 
probability for sentinel variant; Highest PP SNP(s)=SNP(s) with highest posterior probabilities for a credible set; 
Highest PP=value of highest posterior probability for top SNP for a credible set; Highest Flag=annotated SNP is also 
top SNP for credible set 
Supplementary Table 12: Z-scores and P values for eQTL look up in lung tissue resources 
See Excel spreadsheet 
Variants in the 99% credible sets that are associated with gene expression at FDR<5% in an eQTL resource (n=1,111) 
of lung tissue from Laval University62, Canada, Groningen University63, Netherlands and University of British 
Columbia (UBC)64, Canada. The sentinel SNP out of our 279 lung function associated SNPs is given, the SNP most 
highly associated with expression in the 99% credible set of the lung function sentinel, the posterior probability of 
this SNP within the credible set, the gene expression Z-score and P value and the eQTL SNP most highly associated 
with gene expression for that gene (eQTL sentinel). 
This table includes the eQTL data for all genes where there was a variant in the credible set with FDR<5% for 
association with expression. Only genes where the eQTL sentinel is in the credible set were added to our list of 
putative causal genes for downstream analysis. 
Supplementary Table 13: Genes implicated by eQTL or pQTL associations or deleterious variants 
See Excel spreadsheet 
 (-): COPD risk allele (FEV1/FVC decreasing allele) decreases gene expression or protein level. (+): COPD risk allele 
increases gene expression or protein level. Nine GTEx tissues were screened (n up to 388): Artery Aorta (n=267), 
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Artery Coronary (n=152), Artery Tibial (n=388), Colon Sigmoid (n=203), Colon Transverse (n=246), Esophagus 
Gastroesophageal Junction (n=213), Esophagus Muscularis (n=335), Small Intestine Terminal Ileum (n=122), and 
Stomach (n=237) – note direction of gene expression not provided for the genes implicated by these tissues as >1 
tissue is screened. 88 genes were implicated where the eQTL sentinel was in our lung function 99% credible set for 
58 sentinel SNPs; 5 genes were implicated where the pQTL sentinel was in our lung function 99% credible set for 5 
SNPs; 21 genes were implicated by a coding deleterious variant in the 99% credible set for 20 sentinels, giving a 
union across all 3 look ups of 107 unique putative causal genes. Z-scores and P values for the Lung eQTL look up are 
in Supplementary Table 12. 
Footnote: 
Genes implicated by a new signal: ADORA2B, ANGPTL1, ATP2A3, BCHE, BTC, C18ORF8, C2orf54, CEP72, CEPT1, CHI3L2, CHP1, 
CRAT, DHDDS, DRAM2, DST, ECM1, FILIP1L, HMGN2, IER5L, INO80, ITGAV, JAZF1, KIAA0753, LRRC45, MET, MRPS21, NEXN, 
PITPNM3, PKDCC, PPP2R4, RAD51, RPRD2, SENP3, SHISA4, SPATS2L, THBS4, TNFSF13, TTC19, TXNDC17, UBXN2A, ZFP14, ZFP82. 
Genes implicated by a previously reported signal that were not previously implicated56: AAGAB, AP3B1, ARHGEF17, ATXN2L, 
C1QTNF5, CCDC101, CDK2, CENPW, CLN3, CRKRS, DSP, EEF1G, EIF3C, FAM168A, FBXL20, GDF5, IQCH, ITPKA, LTK, NPIPL1, PYGB, 
RPAP1, SBK1, SCARF2, SH2B1, SLMAP, SMAD3, SULT1A1, SULT1A2, TUFM, TYRO3, UQCC1
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Supplementary Table 14: Proteins implicated by pQTL analysis 
Lung function sentinel SNPs where one of the SNPs in the 99% credible set is the most highly associated SNP for a protein (top pSNP) in Sun et al. protein expression 
dataset65 and the association with protein levels is P<5.03x10-8 (5% Bonferroni-adjusted threshold for 276 independent sentinel SNPs x 3,600 plasma protein levels tested). 
Novelty 
Nearest 
Gene Trait Sentinel SNP ID 
Sentinel SNP 
chrom: Position 
(b37) 
Sentinel SNP 
Coded/ 
Noncoded Top pSNP 
Top pSNP chrom: 
Position (b37) 
Top pSNP 
Noncoded 
Top pSNP 
Coded 
Top pSNP 
Beta (SE) P-value Protein 
Novel (Tier 
1) 
C1orf54 PEF rs11205354 1:150,476,516 A/G rs11205385 1:150,476,516 G A 
-0.3153 
(0.0245) 
8.91E-38 ECM1 
Novel (Tier 
1) 
KRTCAP2 FEV1/FVC rs141942982 1:155,153,537 T/C rs111508230 1:155,153,537 C T 
0.2170 
(0.0388) 
2.19E-08 THBS4 
Previous NPNT FEV1 rs34712979 4:106,819,053 A/G rs34712979 4:106,819,053 G A 
-0.2274 
(0.0280) 
4.57E-16 NPNT 
Previous P4HA2-AS1 FVC rs3843503 5:131,567,924 A/G rs11955347 5:131,567,924 G A 
-0.2464 
(0.0245) 
9.12E-24 C1QTNF5 
Previous SCARF2 FEV1/FVC rs9610955 22:20,775,556 T/G rs738086 22:20,775,556 G T 
0.2997 
(0.0318) 
4.79E-21 SCARF2 
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Supplementary Table 15: Pathway analysis 
Gene-based pathway enrichment analyses. Summary of gene-sets overrepresented in known biological pathways and gene ontology (GO) terms. GO term categories (m= 
molecular function, b= biological process, c= cellular component) and levels (1 to 5 with high level GO terms assigned to level 1) are indicated. The effective size is the 
number of genes present in that respective pathway or GO term. Pathways or gene sets represented by only 2 genes from the same association signal have been excluded. 
FDR: False discovery rate. Novel genes from novel and previous signals are marked with a dagger (†) and double dagger (‡), respectively. 
Genes that contain an eQTL that is in our 99% credible sets (thirteen tissues/datasets) and/or 'deleterious' coding variant (n=104 genes) 
 
Enriched biological pathways 
  
P value FDR pathway Genes associated with biological pathway Total size 
of pathway 
gene-set 
4.26E-07 9.33E-05 Molecules associated with elastic fibres ITGAV†; TGFB2; LTBP4; MFAP2; GDF5‡ 30 
9.51E-07 0.000104 Elastic fibre formation ITGAV†; TGFB2; LTBP4; MFAP2; GDF5‡ 35 
3.51E-05 0.00241 Extracellular matrix organization MMP15; TGFB2; LTBP4; DST†; ITGAV†; P4HA2; MFAP2; GDF5‡; ADAM19 294 
0.000158 0.00812 Malaria - Homo sapiens (human) MET†; TGFB2; LRP1; THBS4† 49 
0.000497 0.017 Extracellular vesicle-mediated signaling in recipient cells MET†; TGFB2; SMAD3‡ 30 
0.00059 0.018468 Alpha6Beta4Integrin MET†; DST†; DSP‡; SMAD3‡ 74 
0.001345 0.036822 TGF-Core TGFB2; GDF5†; SMAD3‡ 42 
     
Enriched gene ontology terms 
  
P value FDR Name of GO term (GO term category/level) Genes associated with GO term Total size 
of pathway 
gene-set 
2.39E-05 0.007332 cytoskeleton organization (b/4) TGFB2; LRP1; CEP72†; ARHGEF17‡; DST†; CHP1†; INO80†; DSP‡; SMAD3‡; ITPKA‡; PTPA†; 
CDK2‡; FGD6; MYPN; NEXN†; MAPT; KIAA0753† 
1075 
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0.000271 0.034539 regulation of cartilage development (b/5) TGFB2; PKDCC†; GDF5‡; SMAD3‡ 62 
0.000319 0.025007 ammonium ion metabolic process (b/3) CRAT†; TGFB2; CEPT1†; SLC22A5; CLN3‡; BCHE† 182 
0.00036 0.025007 organelle organization (b/3) TGFB2; CHP1†; INO80†; BTC†; SMAD3‡; AP3B1‡; GDF5‡; ITPKA‡; CLN3‡; RAD51†; UBXN2A†; 
MYPN; NEXN†; FGD6; CEP72†; ARHGEF17; DST†; DSP‡; SH2B1‡; CENPW‡; KIAA0753†; 
ATXN2L‡; LRP1; UQCC1‡; MRPS21†; PTPA†; CDK2‡; MAPT; TTC19†; TUFM‡ 
3207 
0.000371 0.025007 centriole replication (b/3) CDK2‡; KIAA0753†; CEP72† 28 
0.000405 0.004661 protein kinase activity (m/5) TGFB2; LTBP4; CDK12‡; PKDCC†; ITPKA‡; MET†; CDK2‡; BTC†; LTK‡; SBK1‡; TYRO3‡ 646 
0.000413 0.034539 positive regulation of cartilage development (b/5) PKDCC†; GDF5‡; SMAD3‡ 29 
0.000691 0.034539 transforming growth factor beta2 production (b/5) TGFB2; SMAD3‡ 8 
0.000691 0.034539 mitochondrial respiratory chain complex III assembly (b/5) UQCC1‡; TTC19† 8 
0.000786 0.022497 transmembrane receptor protein kinase activity (m/4) LTK‡; MET†; LTBP4; TYRO3‡ 82 
0.000939 0.037577 positive regulation of ossification (b/5) NPNT; TGFB2; PKDCC†; SMAD3‡ 86 
0.001016 0.045883 microtubule-based process (b/3) AP3B1‡; CEP72†; DST†; CHP1†; INO80†; PTPA†; CDK2‡; CLN3‡; MAPT; KIAA0753† 611 
0.001136 0.045883 extracellular structure organization (b/3) MMP15; TGFB2; THSD4; ITGAV†; SMAD3‡; NPNT; MFAP2 318 
0.001481 0.049872 phosphorus metabolic process (b/3) DHDDS†; CHP1†; TGFB2; BTC†; SMAD3‡; PKDCC†; ADORA2B†; MET†; CDK12‡; GDF5‡; ITPKA‡; 
CARD9; CLN3‡; RAD51†; SULT1A1‡; NUDT5; SULT1A2‡; LTK‡; SBK1‡; TYRO3‡; INPP5E; RSRC1; 
CEPT1†; ITGAV†; NPNT; PTPA†; CDK2‡; PITPNM3† 
3164 
0.00149 0.022497 phosphatase binding (m/4) AP3B1‡; MET†; PTPA†; MAPT; SMAD3‡ 165 
0.001512 0.04837 regulation of chondrocyte differentiation (b/5) PKDCC†; GDF5‡; SMAD3‡ 45 
0.001824 0.022497 phosphotransferase activity, alcohol group as acceptor (m/4) TGFB2; LTBP4; CDK12‡; PKDCC†; ITPKA‡; MET†; CDK2‡; BTC†; LTK‡; SBK1‡; TYRO3‡ 777 
0.001846 0.04837 regulation of neuron death (b/5) TGFB2; LRP1; CHP1†; GDF5‡; CLN3‡; TYRO3‡ 255 
0.001935 0.04837 catechol-containing compound metabolic process (b/5) TGFB2; SULT1A1‡; SULT1A2‡ 49 
0.002171 0.012484 transforming growth factor beta receptor binding (m/5) TGFB2; GDF5‡; SMAD3‡ 51 
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0.002884 0.026674 transforming growth factor beta binding (m/4) LTBP4; ITGAV† 16 
0.003486 0.016037 protein phosphatase binding (m/5) AP3B1‡; MET†; MAPT; PTPA† 123 
0.004122 0.030499 kinase activity (m/4) TGFB2; LTBP4; CDK12‡; PKDCC†; ITPKA‡; MET†; CDK2‡; BTC†; LTK‡; SBK1‡; TYRO3‡ 864 
0.004328 0.016592 transmembrane receptor protein tyrosine kinase activity (m/5) LTK‡; MET†; TYRO3‡ 65 
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Supplementary Table 16: Stratified LD score regression analysis of FEV1/FVC and FVC heritability enrichment at lung and smooth-muscle specific histone marks 
#Proportion of SNP-chip heritability explained by overlapping SNPs 
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Cell type Chromatin 
mark 
Proportion of 
overlapping SNPs 
Trait Proportion of 
heritability# 
Proportion of heritability 
standard error 
Fold Enrichment Enrichment 
standard error 
Enrichment 
P-value 
Fetal Lung H3K4me3 1.07% FEV1/FVC 14.80% 0.024 13.78 2.23 3.40E-08 
  H3K4me3 
 
FVC 9.20% 0.018 8.57 1.65 8.59E-06 
  H3K4me1 6.99% FEV1/FVC 57.09% 0.04 8.16 0.57 2.85E-25 
  H3K4me1 
 
FVC 35.84% 0.027 5.13 0.39 4.19E-21 
  H3K9ac 1.30% FEV1/FVC 18.72% 0.027 14.40 2.09 1.36E-10 
   H3K9ac   FVC 11.74% 0.021 9.03 1.58 9.90E-07 
Lung H3K4me3 0.56% FEV1/FVC 4.66% 0.016 8.29 2.82 0.009967 
  H3K4me3 
 
FVC 4.47% 0.016 7.95 2.83 0.015267 
  H3K4me1 1.75% FEV1/FVC 12.70% 0.024 7.24 1.39 1.32E-05 
   H3K4me1   FVC 6.99% 0.017 3.99 0.94 0.001545 
Colon Smooth Muscle H3K4me3 1.44% FEV1/FVC 14.39% 0.021 9.99 1.47 3.95E-09 
  H3K4me3 
 
FVC 10.67% 0.017 7.41 1.2 2.80E-07 
  H3K4me1 3.52% FEV1/FVC 26.77% 0.028 7.61 0.78 2.04E-15 
  H3K4me1 
 
FVC 18.02% 0.021 5.12 0.61 7.99E-11 
  H3K9ac 0.57% FEV1/FVC 5.29% 0.013 9.32 2.33 0.000339 
  H3K9ac 
 
FVC 3.14% 0.012 5.54 2.06 0.029484 
  H3K27ac 2.54% FEV1/FVC 15.53% 0.022 6.12 0.88 1.97E-08 
   H3K27ac   FVC 11.02% 0.015 4.35 0.61 1.47E-07 
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Stomach Smooth Muscle H3K4me3 2.00% FEV1/FVC 20.39% 0.022 10.15 1.1 1.19E-14 
  H3K4me3 
 
FVC 13.79% 0.018 6.86 0.9 3.56E-10 
  H3K4me1 2.39% FEV1/FVC 21.13% 0.023 8.83 0.95 4.51E-14 
  H3K4me1 
 
FVC 14.85% 0.02 6.20 0.82 9.61E-10 
  H3K9ac 1.40% FEV1/FVC 14.55% 0.022 10.38 1.55 5.12E-09 
  H3K9ac 
 
FVC 9.27% 0.017 6.62 1.21 4.98E-06 
  H3K27ac 2.67% FEV1/FVC 17.72% 0.023 6.64 0.88 9.50E-10 
   H3K27ac   FVC 10.22% 0.015 3.83 0.58 2.03E-06 
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Supplementary Table 17: DeepSEA prediction of functional effect 
See Excel spreadsheet. 
DeepSEA predictions for the SNPs in the 99% credible sets (total n=9446 SNPs) in lung-related cell lines from the 
RoadMap Epigenome and ENCODE projects. We queried four lung-related cell lines (foetal lung, foetal lung 
fibroblasts [IMR90], human lung fibroblasts [NHLF] and adenocarcinomic human alveolar basal epithelial cells 
[A549]) for which 55 chromatin features and transcription factor binding sites were measured. The absolute 
difference between reference and alternative allele is shown. Only the results for the 161 SNPs with a predicted 
functional effect (i.e. absolute difference ≥0.1) in ≥1 cell line are presented. SNPs which have the highest posterior 
probability in their respective credible sets are coloured in red. Non-significant results (i.e. absolute difference 
between reference and alternative allele <0.1) are replaced with a “-“ for clarity. E-values (i.e. the expected 
proportion of SNPs with larger predicted effect for this chromatin feature based on empirical distributions of 
predicted effects for 1000 Genomes SNPs) for each result are presented in brackets. E-values<0.05 and <0.01 are 
highlighted in red and green, respectively. 
Supplementary Table 18: Druggability analysis 
See Excel spreadsheet. Please note that it is possible to filter this table using the drop-down arrows at the top of each 
column. 
Table showing drugs interacting with either high-priority genes that were identified in eQTL or pQTL analysis or 
annotated as deleterious (N=107) (Supplementary Table 13). 
The 107 genes were queried against gene-drug interactions within the Drug-Gene Interactions Database (DGIDB) 
(http://www.dgidb.org/data/). The 68 drugs (identified from CHEMBL interactions) that mapped to these genes 
were mapped to CHEMBL IDs and indications (as Medical Subject Headings, or ‘MeSH’ terms, 
https://www.ebi.ac.uk/chembl/drug/indications). For each gene, the sentinel SNP that implicated this gene is given. 
Drug names associated with each gene, plus CHEMBL IDs, and drug indications (with maximum development phase 
in brackets) are also shown. 
Column explanations:  
1. Drug=compound/drug name; 
2. CHEMBL_ID=compound identification number from CHEMBL; 
3. OriginalGeneAndSource=The name(s) of the gene (amongst the set of 107 high priority genes) interacting 
with the drug; 
4. IndicationPhase=Drug indication (Phase). Phase 1: Testing of drug on healthy volunteers for dose-ranging; 
Phase 2: Testing of drug on patients to assess efficacy and safety; Phase 3: Testing of drug on patients to 
assess efficacy, effectiveness and safety; and Phase 4: Approval of drug and post-marketing surveillance. 
5. MAB=Drug is a monoclonal antibody;  
6. OriginalGenesPathway=the gene given in the ‘Original Gene and Source’ column is a gene identified in the 
‘Enriched Biological Pathways’ shown in Supplementary Table 15; 
7. Cancer=the drug is used to treat some form of cancer;  
8. Phase3or4=the drug has at least one indication annotated as Phase 3 or 4;  
9. AsthmaCOPD=the drug is already indicated as being used in asthma or COPD;  
10. Novelty=the drug is implicated for use by genes identified from novel signals in this GWAS.  
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Supplementary Table 19: UK Biobank and China Kadoorie Biobank COPD and FEV1/FVC weighted genetic risk score association results (per-allele and per standard deviation) 
by ancestry 
Individuals in UKB Biobank and China Kadoorie Biobank were included for this analysis, and UK Biobank individuals were divided into ancestry groups as described in 
Supplementary Figure 1. The weighted genetic risk score was tested for association with COPD and FEV1/FVC. COPD was defined as FEV1/FVC<0.7 and FEV1<80% predicted 
(i.e. corresponding to GOLD 2-4 standards). The COPD model (a logistic regression, with COPD coded as COPD [1] vs. no COPD [0]) was adjusted as described in the Online 
Methods. The COPD model was only fitted in ancestral groups with >100 COPD cases. For the FEV1/FVC model, linear regression was used. The phenotype was as prepared 
for the main GWAS described in this paper (see Online Methods). 
Ancestry per Allele per Standard Deviation P Total N N Control N Case Mean risk 
score 
SD  
risk 
score 
Effect size* 
(OR/Beta) 
95LCI 95UCI Effect size* 
(OR/Beta) 
95LCI 95UCI 
COPD 
UK Biobank African 1.033 1.015 1.050 1.348 1.152 1.577 1.92E-04 4225 4053 172 305.95 9.26 
UK Biobank South Asian 1.030 1.020 1.041 1.414 1.254 1.594 1.42E-08 6358 6046 312 308.22 11.66 
UK Biobank Chinese**        1607 1558 49 302.38 11.47 
UK Biobank European*** 1.030 1.029 1.032 1.436 1.411 1.461 <1e-300 303570 288467 15103 307.78 12.16 
UK Biobank Mixed African & European        1208 1153 55 305.70 10.67 
UK Biobank Mixed Other 1.035 1.024 1.046 1.506 1.325 1.712 3.65E-10 6033 5752 281 305.58 12.04 
China Kadoorie Biobank** 1.017 1.014 1.019 1.219 1.182 1.256 3.31E-40 75580 69567 6013 298.22 11.84 
FEV1/FVC 
UK Biobank African -0.009 -0.013 -0.006 -0.086 -0.116 -0.056 2.12E-08 4225 
  
305.95 9.26 
UK Biobank South Asian -0.015 -0.018 -0.013 -0.181 -0.205 -0.156 3.72E-47 6358 
  
308.22 11.66 
UK Biobank Chinese** -0.012 -0.017 -0.008 -0.142 -0.191 -0.093 1.44E-08 1607 
  
302.38 11.47 
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UK Biobank European*** -0.018 -0.019 -0.018 -0.224 -0.227 -0.221 <1e-300 303570 
  
307.78 12.16 
UK Biobank Mixed African & European -0.016 -0.022 -0.011 -0.176 -0.231 -0.120 7.01E-10 1208 
  
305.70 10.67 
UK Biobank Mixed Other -0.015 -0.018 -0.013 -0.186 -0.211 -0.162 7.00E-48 6033   305.58 12.04 
China Kadoorie Biobank** -0.007 -0.007 -0.006 -0.078 -0.085 -0.071 2.51E-98 72796   298.22 11.84 
*Effect sizes are odds ratios for COPD results, and change in Z-score units for FEV1/FVC results 
**For details on missing SNPs in UK Biobank Chinese ancestry subjects, and China Kadoorie Biobank participants, see Online Methods 
***Europeans in UK Biobank were the discovery sample for many of the variants in the risk score, which explains the very low p-values in this subgroup. 
Supplementary Table 20: Demographics of COPD case-control cohorts included in risk score included in risk score analysis 
Descriptive statistics for each cohort are given separately for cases and controls, for five cohorts: the COPD Gene study, the ECLIPSE study (Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-points), GenKOLS (the Bergen, Norway COPD cohort), NETT/NAS (the National Emphysema Treatment Trial [NETT] and 
the Normative Aging Study [NAS]) and the SPIROMICS study. Abbreviation: SD=standard deviation; age is given in years, height in centimetres, FEV1 and FVC litres. 
Cohort Case-control 
status 
Total N % female Age 
range 
Mean age 
(SD) 
Height 
range 
Mean height 
(SD) 
N with 
spirometry 
data 
Mean FEV1 
(SD) 
Mean FVC 
(SD) 
Mean 
FEV1/FVC 
(SD) 
% ever smokers (N 
with ever smoking 
data available) 
Pack-years range (N 
with pack-years data 
available) 
Mean 
pack-
years (SD) 
COPDGene  
(African-American 
Population) 
Cases 910 44.84 45-81 58.6 
(8.15) 
137-208 170.96 
(10.1) 
910 1.39 (0.63) 0.534 
(0.121) 
2.546 
(0.879) 
100 (910) 10 - 162 (910) 42.69 
(23.48) 
Controls 1556 40.94 45-80 52.84 
(6.01) 
142-203 171.15 
(9.33) 
1556 2.768 
(0.644) 
0.785 
(0.05) 
3.535 
(0.839) 
100 (1556) 10 - 160.4 (1556) 36.11 
(19.1) 
COPDGene  
(Non-Hispanic White 
Population) 
Cases 3068 45.14 45-81 64.38 
(8.28) 
134-196 169.72 
(9.45) 
3068 1.424 
(0.659) 
2.817 
(0.908) 
0.495 
(0.134) 
100 (3068) 10 - 237.6 (3068) 54.89 
(27.12) 
Controls 2110 51.47 45-81 59.18 
(8.64) 
140-198 169.54 
(9.38) 
2110 2.924 
(0.679) 
3.817 
(0.892) 
0.768 
(0.044) 
100 (2110) 10 - 172.5 (2110) 37.34 
(20.14) 
ECLIPSE Cases 1713 32.87 40-75 63.64 
(7.1) 
142-201 169.54 
(9.02) 
1713 1.213 
(0.487) 
2.766 
(0.873) 
0.441 
(0.111) 
100 (1713) 6 - 220 (1713) 50.5 
(27.47) 
Controls 147 42.86 40-74 57.32 
(9.55) 
151-196 171.24 
(9.69) 
147 3.164 
(0.779) 
4.085 
(1.03) 
0.778 
(0.054) 
100 (147) 10 - 230 (147) 31.01 
(25.94) 
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GenKOLS Cases 836 39.23 40-90 65.44 
(10.1) 
146-197 170 (9.02) 836 1.477 
(0.699) 
2.863 
(0.957) 
0.502 
(0.126) 
100 (836) 3 - 130 (836) 31.88 
(18.62) 
Controls 692 48.84 40-88 55.43 
(9.74) 
151-200 172.05 
(8.79) 
692 3.214 
(0.722) 
4.169 
(0.935) 
0.772 
(0.041) 
100 (692) 2.5 - 90 (692) 19.4 
(13.61) 
NETT/NAS Cases 374 36.1 40-85 67.47 
(5.76) 
142-190 168.76 
(9.53) 
374 0.726 
(0.236) 
2.299 
(0.775) 
0.324 
(0.064) 
100 (374) 12 - 260 (371) 66.25 
(30.66) 
Controls 429 0 48-89 69.86 
(7.5) 
156-192 174.46 
(6.79) 
429 3.032 
(0.507) 
3.83 
(0.627) 
0.793 
(0.053) 
100 (429) 10 - 185.5 (429) 40.69 
(27.79) 
SPIROMICS Cases 988 44 41-89 65.74 
(7.62) 
141-197 170.05 
(9.64) 
988 1.539  
(0.605) 
3.194  
(0.927) 
0.48 (0.13) 100 (988) 20.0 - 450 (988) 56.11 
(28.78) 
Controls 537 53 40-80 62.95 
(9.0) 
149-205 169.54 
(9.62) 
537 2.824 
(0.705) 
3.678 
(0.913) 
0.77 (0.04) 100 (537) 20.0 - 400 (537) 44.76 
(26.36) 
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Supplementary Table 21: External case-control studies COPD risk score association results (per-allele and per standard deviation) 
Results of the association between genetic risk scores and COPD risk are given for both weighted (top) and unweighted (bottom) risk scores (comprising 279 novel and 
previous signals), for five studies: the COPD Gene study, the ECLIPSE study (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), GenKOLS (the 
Bergen, Norway COPD cohort), NETT/NAS (the National Emphysema Treatment Trial [NETT] and the Normative Aging Study [NAS]) and the SPIROMICS study. COPD Gene is 
stratified into African-American and Non-hispanic white subgroups. Effect sizes and 95% confidence intervals are given on two scales: a per-Allele (i.e. raw) scale, and a per 
standard deviation (SD) scale. Standard deviations for the weighted and unweighted risk scores are given for each cohort separately. Abbreviations: AA=African-American; 
Nhw=Non-Hispanic white; OR=odds ratio; 95LCI/UCI=lower and upper bounds of 95% confidence intervals; P=p-value; N=sample size. A sensitivity analysis was also run, 
excluding SNP rs13116999 (see ‘Discussion’ of manuscript). The per-allele meta-analytic estimate was consistent after excluding this SNP. *The odd ratios per standard 
deviation increase in the risk score were estimated as: exp(logOR on the per allele scale × standard deviation of the weighted risk score). **Approximated in R as 
sqrt(sum(SD^2*(N-1))/sum(N-1)), where N is a vector of sample sizes, and SD is a vector of standard deviations. 
Ancestry Study group per Allele P per Standard Deviation* P* N Mean risk 
score 
SD  
risk score OR 95LCI 95UCI OR 95LCI 95UCI Total Cases Controls 
 Weighted   
African COPDGene (AA) 1.023 1.014 1.032 8.36E-07 1.255 1.147 1.374 8.36E-07 2466 910 1556 306.16 10.09 
               
European COPDGene (NHW) 1.036 1.03 1.041 1.97E-41 1.535 1.442 1.634 1.97E-41 5178 3068 2110 307.72 12.25 
European ECLIPSE 1.039 1.023 1.055 1.42E-06 1.585 1.314 1.912 1.42E-06 1860 1713 147 309.80 12.16 
European GenKOLS 1.042 1.031 1.052 8.99E-15 1.623 1.436 1.834 8.99E-15 1528 836 692 308.05 11.89 
European NETT/NAS 1.032 1.017 1.047 3.13E-05 1.464 1.223 1.751 3.13E-05 803 374 429 307.54 12.16 
European SPIROMICS 1.037 1.027 1.046 4.47E-14 1.539 1.376 1.721 4.47E-14 1525 988 537 307.90 11.95 
Meta-analysis of 5 European-ancestry study groups 1.037 1.033 1.041 1.72E-75 1.546 1.476 1.620 1.48E-75 10894 6979 3915 308.13 12.14** 
 Unweighted   
African COPDGene (AA) 1.015 1.005 1.025 0.00251 1.147 1.049 1.254 0.00251 2466 910 1556 298.62 9.33 
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European COPDGene (NHW) 1.034 1.028 1.04 3.03E-28 1.413 1.329 1.503 3.03E-28 5178 3068 2110 294.74 10.36 
European ECLIPSE 1.037 1.02 1.055 2.45E-05 1.476 1.232 1.769 2.45E-05 1860 1713 147 296.41 10.63 
European GenKOLS 1.046 1.033 1.059 7.58E-13 1.561 1.382 1.764 7.58E-13 1528 836 692 295.60 9.96 
European NETT/NAS 1.019 1.002 1.035 2.73E-02 1.212 1.022 1.439 2.73E-02 803 374 429 294.69 10.48 
European SPIROMICS 1.036 1.025 1.047 1.62E-10 1.435 1.284 1.603 1.62E-10 1525 988 537 294.20 10.27 
Meta-analysis of 5 European-ancestry study groups 1.035 1.030 1.039 6.71E-52 1.425 1.362 1.492 4.45e-52 10894 6979 3915 295.07 10.35** 
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Supplementary Table 22: COPD risk score association results in external case-control studies (per-decile) 
Within each study group, individuals were divided according to their value of the weighted genetic risk score. Logistic 
models were then fitted for each decile, comparing odds of COPD between members of each decile (2-10) and the 
lowest decile (1, the reference decile). Results were meta-analysed by fixed-effects across the European-ancestry 
subjects of COPDGene (Non-hispanic white participants), ECLIPSE, GenKOLS, NETT/NAS, SPIROMICS. Results are 
presented separately for African-American participants of the COPDGene study 
Decile Meta-analysis of 5 European Cohorts* COPDGene (African-American) 
OR LCI UCI P OR LCI UCI P 
1 1.000 
   
1.000 
   
2 1.470 1.207 1.790 1.26E-04 0.881 0.566 1.370 0.573 
3 1.572 1.289 1.918 7.97E-06 1.407 0.927 2.135 0.109 
4 2.092 1.712 2.555 4.94E-13 1.281 0.838 1.961 0.253 
5 2.045 1.678 2.491 1.23E-12 1.639 1.083 2.481 0.020 
6 2.033 1.666 2.481 2.93E-12 1.214 0.807 1.825 0.352 
7 2.520 2.054 3.091 7.21E-19 1.215 0.784 1.882 0.383 
8 2.800 2.282 3.435 5.76E-23 1.376 0.902 2.101 0.139 
9 3.961 3.213 4.883 5.15E-38 1.895 1.255 2.863 2.38E-03 
10 4.731 3.793 5.900 3.00E-43 2.660 1.753 4.036 4.25E-06 
*COPDGene (Non-hispanic white participants), ECLIPSE, GenKOLS, NETT/NAS, SPIROMICS 
 
Supplementary Table 23: Results for single-variant PheWAS 
See Excel spreadsheet. 
Results are given for 2,411 traits studied. Associations between each trait and each of the 279 SNPs entering the 
genetic risk score were carried out. Total sample sizes (N), as well as numbers of cases and controls are given. Odds 
ratios (OR) are given for binary traits, and beta coefficients are given for continuous traits. Confidence intervals 
(LCI95, UCI95) and P values are also provided, along with false discovery rates. ‘FDR.Flag’ denotes associations 
passing an FDR of <0.01 (only associations passing an FDR of 1% are included in this table). ‘Quant.Resp.Trait’ is a flag 
variable indicating PheWAS results for those SNPs featuring in the main GWAS. ‘Figure.Name’ denotes the short 
plain English label used in Figure 4 in the main text, allowing for cross reference. Information on each SNP is also 
given (SNP name, chromosome (CHR), position (BP), effect and non-effect alleles, allele frequency, and imputation 
quality). Results of all 2,411*279 SNP-trait associations are available from the authors on request, but are not 
provided here due to their size. 
To compare the effect directions in these PheWAS results with the effect direction on lung function, please cross-
reference with Supplementary Table 28. 
 75 
 
Supplementary Table 24: Lung function SNPs associated with asthma and eosinophil counts. 
25 of 279 lung function SNPs that are associated with asthma in the UK Biobank PheWAS (FDR<1%) for the UK Biobank category M2W_asthma, except for *HES_asthma 
(rs9385988) and †TA_NI_pediatric_asthma_under16yo (rs2811415, rs1215 & rs17577877). 12 in bold are additionally associated in the UK Biobank PheWAS with eosinophil 
counts (FDR<%1 for Eosinophil_count or Eosinophil_percentage). 8 SNPs are in LD (r2>0.1) with previously reported asthma SNPs. The directions, which correspond to the 
UKB+SpiroMeta lung function meta-analysis, the asthma PheWAS, and the published asthma association (if known) are + for worse lung function and increased asthma risk 
and - for better lung function and decreased asthma risk (• risk allele not reported for rs3001426). 
 Lung function (meta-analysis of UK Biobank & SpiroMeta) Asthma PheWAS Asthma published 
Directions Nearest gene rsid Position (b37) 
Coded/ 
Noncoded 
Coded 
Freq. Phenotype 
Novel/ 
previous Effect (se) P OR (95% CI) P rsid r2 
IL1RL1 rs12470864 2:102926362 A/G 38.5% FEV1/FVC Tier 1 -0.02 (0.002) 1.04E-16 1.1 (1.08-1.11) 1.72E-40 rs142010166 0.952 +++ 
EEFSEC rs2811415 3:127991527 A/G 16.0% FEV1/FVC previous 0.031 (0.003) 2.84E-21 0.93 (0.9-0.96)† 3.42E-05†   -- 
LOC100507661 rs56341938 3:168715808 A/G 48.6% FEV1 previous -0.024 (0.002) 4.17E-25 1.03 (1.02-1.04) 3.39E-05   ++ 
NPNT rs34712979 4:106819053 A/G 25.6% FEV1/FVC previous -0.068 (0.003) 4.18E-134 1.04 (1.02-1.05) 9.31E-06   ++ 
HHIP-AS1 rs12504628 4:145436324 T/C 60.4% FEV1/FVC previous -0.07 (0.002) 5.99E-180 1.03 (1.01-1.04) 6.38E-05   ++ 
P4HA2-AS1 rs7713065 5:131788334 A/C 26.5% FVC previous 0.009 (0.003) 9.96E-04 1.09 (1.07-1.1) 7.88E-28 rs374983367 0.982 -++ 
HTR4 rs7715901 5:147856392 A/G 60.4% FEV1/FVC previous -0.05 (0.003) 2.44E-92 1.03 (1.02-1.04) 3.08E-05   ++ 
ADAM19 rs10515750 5:156810072 T/C 7.0% FEV1/FVC previous -0.053 (0.005) 2.38E-30 1.07 (1.04-1.1) 6.58E-07   ++ 
ZSCAN31 rs34864796 6:27459923 A/G 12.5% PEF previous -0.053 (0.004) 1.02E-43 1.06 (1.03-1.08) 1.29E-07   ++ 
AGER rs2070600 6:32151443 T/C 6.3% FEV1/FVC previous 0.145 (0.005) 3.00E-189 1.15 (1.12-1.18) 2.20E-24 rs40486068 0.252 -+- 
HLA-DQB1 rs3844313 6:32635629 A/G 25.5% FEV1/FVC previous -0.044 (0.003) 1.06E-54 1.08 (1.06-1.09) 4.06E-20 rs927337369 0.234 +++ 
VTA1 rs9385988 6:142560957 A/G 72.3% FEV1 Tier 1 -0.028 (0.003) 1.40E-26 1.04 (1.02-1.07)* 8.02E-05*   ++ 
JAZF1 rs1513272 7:28200097 T/C 50.0% FEV1 Tier 1 0.02 (0.002) 1.11E-17 0.97 (0.95-0.98) 1.32E-06 rs697795567 0.255 --- 
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 Lung function (meta-analysis of UK Biobank & SpiroMeta) Asthma PheWAS Asthma published 
Directions Nearest gene rsid Position (b37) 
Coded/ 
Noncoded 
Coded 
Freq. Phenotype 
Novel/ 
previous Effect (se) P OR (95% CI) P rsid r2 
PPP1R3B rs330939 8:9018590 T/G 62.1% FEV1/FVC Tier 1 0.023 (0.003) 4.46E-21 0.97 (0.96-0.98) 3.99E-05   -- 
LOC101929563 rs10965947 9:23588583 T/C 45.9% FEV1/FVC previous 0.022 (0.002) 4.27E-20 0.97 (0.96-0.98) 1.57E-05   -- 
IER5L rs967497 9:131943843 A/G 31.0% FEV1 Tier 2 0.015 (0.003) 2.79E-09 0.97 (0.95-0.98) 2.56E-06   -- 
SUOX rs772920 12:56390364 C/G 66.6% FEV1 previous 0.015 (0.003) 6.76E-10 0.94 (0.93-0.96) 4.99E-16 rs170170468 0.888 --- 
LRP1 rs11172113 12:57527283 T/C 58.9% FEV1/FVC previous -0.023 (0.002) 7.04E-21 0.96 (0.95-0.98) 1.40E-07 rs300142670 0.578 +-• 
SMAD3 rs8025774 15:67483276 T/C 22.4% FVC previous -0.022 (0.003) 5.63E-15 0.94 (0.92-0.95) 6.89E-15   +- 
SH3GL3 rs12438269 15:84502549 T/C 20.7% FEV1/FVC previous 0.031 (0.003) 5.97E-26 0.96 (0.94-0.97) 6.66E-07   -- 
CLDN7 rs1215 17:7163350 A/G 85.7% FVC Tier 2 0.022 (0.003) 9.64E-11 0.93 (0.9-0.96)† 2.77E-06†   -- 
TNFSF12-TNFSF13 rs4968200 17:7448457 C/G 14.2% FEV1 Tier 2 -0.022 (0.003) 4.54E-11 1.05 (1.03-1.07) 1.90E-06   ++ 
FBXL20 rs8067511 17:37611352 T/C 84.5% FVC previous 0.018 (0.003) 2.36E-08 0.94 (0.92-0.96) 7.00E-11   -- 
MAPT-AS1 rs17577877 17:44208218 A/G 77.9% FEV1 previous 0.042 (0.003) 4.71E-48 1.05 (1.02-1.08)† 3.51E-04†   -+ 
SLC2A4RG rs6062304 20:62351539 A/T 32.4% FVC previous 0.029 (0.003) 4.04E-31 0.97 (0.96-0.99) 1.84E-04 rs601103367 0.480 --- 
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Supplementary Table 25: Results for PheWAS of weighted genetic risk score 
See Excel spreadsheet. 
Results are given for 2,453 traits studied. The exposure was the 279-SNP weighted genetic risk score. Each trait was 
assigned a disease category=‘Final.Category’). Total sample sizes (N), as well as numbers of cases and controls are 
given. Odds ratios (OR) are given for binary traits, and beta coefficients are given for continuous traits. Confidence 
intervals (LCI95, UCI95) and P values are also provided, along with false discovery rates. ‘FDR.Flag’ denotes 
associations passing an FDR of <0.01. ‘Quant.Resp.Trait’ is a flag variable indicating PheWAS results for those SNPs 
featuring in the main GWAS. ‘Figure.Name’ denotes the short plain English label used in the Figure in the main text, 
allowing for cross reference. 
Supplementary Table 26: Look-up of new and previously reported lung function signals in GRASP and GWAS catalog 
See Excel spreadsheet. 
Tabulated results of a lookup of sentinel variants and variants in their respective 99% credible sets against all 
associations P< 5x10-8 in the EBI GWAS catalog (https://www.ebi.ac.uk/gwas/ ) and GRASP 
(https://grasp.nhlbi.nih.gov/Overview.aspx). Associations relating to methylation, expression, metabolite or protein 
levels, as well as associations with lung function were removed. The table first shows the ID and genomic position of 
the sentinel variant that was associated with the trait in question (either the sentinel variant, or one of its 99% 
credible set variants was associated with the trait). Next, the details of the association with lung function for this 
variant in the current study are shown (trait, whether the signal identified in Tier 1 or Tier 2). If this signal is not a 
novel signal, details of the original sentinel variant and trait are given. For retrieved studies mapping to the sentinel 
(or its credible set variants), all reported genes across the studies of interest are given, along with all traits, and the 
PUBMED IDs of the papers from which associations were retrieved. 
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Supplementary Table 27: LD score regression results 
Results for the regression of each trait FEV1, FVC, FEV1/FVC and PEF against the LD score of each variant are shown. Total Observed scale h2: Estimate of heritability, 
Lambda GC: Usual lambda used for genomic control: inflation due to both confounding and polygenicity, Mean χ2 : Mean χ2 statistic from the association testing, Intercept: 
Intercept of the LD score regression (estimate of inflation due to confounding but not polygenicity; suggested as a more appropriate genomic-control factor), Ratio: 
Proportion of total inflation due to confounding (Intercept-1)/(Mean χ2 -1). 95% confidence intervals are shown in brackets. 
 
UK Biobank (n=321,047) FEV1 FVC FEV1/FVC PEF 
Total Observed scale h2 0.185 (0.173, 0.198) 0.187 (0.175, 0.199) 0.211 (0.19, 0.232) 0.155 (0.14, 0.17) 
Lambda GC 1.841 1.841 1.841 1.695 
Mean Chi^2 2.328 2.355 2.578 2.138 
Intercept 1.119 (1.096, 1.142) 1.139 (1.113, 1.164) 1.193 (1.162, 1.225) 1.133 (1.106, 1.159) 
Ratio 0.09 (0.072, 0.107) 0.102 (0.083, 0.121) 0.123 (0.103, 0.142) 0.117 (0.094, 0.139) 
 
SpiroMeta (n=79,055) FEV1 FVC FEV1/FVC PEF 
Total Observed scale h2 0.126 (0.107, 0.145) 0.116 (0.097, 0.134) 0.095 (0.077, 0.113) 0.094 (0.055, 0.134) 
Lambda GC 1.146 1.146 1.114 1.017 
Mean Chi^2 1.194 1.178 1.141 1.017 
Intercept 0.998 (0.983, 1.013) 1.003 (0.986, 1.019) 0.993 (0.979, 1.007) 0.972 (0.959, 0.986) 
Ratio <0 0.014 (-0.078, 0.106) <0 <0 
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Meta-analysis (n up to 400,102) FEV1 FVC FEV1/FVC PEF 
Total Observed scale h2 0.154 (0.144, 0.165) 0.152 (0.142, 0.161) 0.152 (0.137, 0.167) 0.131 (0.118, 0.143) 
Lambda GC 1.757 1.781 1.581 1.489 
Mean Chi^2 2.291 2.261 2.272 1.919 
Intercept 1.041 (1.018, 1.065) 1.04 (1.015, 1.065) 1.033 (1.006, 1.061) 1.006 (0.982, 1.031) 
Ratio 0.032 (0.014, 0.05) 0.032 (0.012, 0.051) 0.026 (0.005, 0.048) 0.007 (-0.02, 0.034) 
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Supplementary Table 28: Weights for COPD risk score 
See Excel spreadsheet. 
Weights for COPD risk score. Weights for each the 279 variants were selected from the FEV1/FVC ratio results for UK 
Biobank or SpiroMeta. The FEV1/FVC ratio decreasing allele was chosen (generally this will be the COPD risk 
increasing allele, and that is how the term is used in this paper). To minimise the risk of winner’s curse bias, the 
study which was not used in the discovery of a given signal was used as the source of the weight. For previously 
reported signals, this meant that most weights were taken from UK Biobank (if UK Biobank was used in signal 
discovery, SpiroMeta was used to derive weights). For novel signals identified in this study, the source of weight 
depended on whether the signal was identified in the two-stage (Tier 1) approach, or the joint, one-stage (Tier 2) 
approach. SpiroMeta was the source of weights for two-stage signals, and for one-stage signals, the smallest 
absolute effect size from UK Biobank or SpiroMeta was chosen. Betas are the FEV1/FVC ratio effect size from the 
study defined in the column ‘Source’. Weights were calculated as the beta for a given variant, divided by the sum of 
all 279 betas, multiplied by the number of variants (279), such that the sum of the weights added to 279.  
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Supplementary Table 29: Single-variant associations for 279 SNPs with COPD susceptibility in UK Biobank, China 
Kadoorie Biobank, and a fixed-effect meta-analysis of five European-ancestry cohorts 
This table shows association results between the 279 variants and COPD susceptibility in ancestral groups of UK 
Biobank (unrelated individuals), China Kadoorie Biobank, COPDGene African Americans, and results from the fixed-
effect meta analyses of five European-ancestry cohorts (see also Supplementary Figure 9). Case and control 
numbers for each group studied are given above the column headings.  
In UK Biobank, single-variant associations with COPD susceptibility were calculated separately for the 279 SNPs using 
SNPTEST v2.5. Associations were adjusted for age, age2, sex, height, smoking status, 10 principal components and 
genotyping array. 
Abbreviations: Chr=Chromosome; BP=position (GRCh37); Risk=FEV1/FVC decreasing allele in GWAS; NonRisk=other 
allele; FreqRisk=allele frequency of risk allele in the 321,047 UK Biobank Europeans studied in the main GWAS; 
Beta=effect estimate; SE=standard error; P=P-value 
Four variants were unavailable in China Kadoorie Biobank, and twelve additional variants required a proxy, given in 
the column 'CKB_Proxy_used', along with the corresponding risk allele for the proxy variant. Two variants were 
unavailable in UK Biobank Chinese subjects.  
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